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The Role of Poly (ADP-Ribose) Polymerase-1 Inhibitors: Prevention Of Non 
Glutathione-Dependent Carbon Tetrachloride-Induced Hepatotoxicity 
Paul Christopher Grivas 
ABSTRACT 
Carbon tetrachloride (CCl4) is a hepatotoxicant known to elevate alanine 
aminotransferase (ALT) and other liver enzyme levels, and cause lipid peroxidation, as 
well as centrilobular necrosis.  A number of poly ADP-ribose polymerase (PARP) 
inhibitors were administered via intraperitoneal (i.p.) injections to male ICR mice as co-
treatments at various time intervals relative to the CCl4.  Aminophylline, a water soluble 
complex consisting of two molecules of theophylline bridged by ethylene diamine, was 
administered one-half hour, one hour and two hours after CCl4.  The levels of ALT in the 
serum, as well as malondialdehyde and its equivalent markers of oxidative damage in the 
liver, were significantly reduced by aminophylline, relative to those in mice receiving 
only CCl4.  The hepatoprotective effects of aminophylline were confirmed via the 
examination of histopathologic samples from the livers of mice receiving aminophylline 
in conjunction with CCl4 as opposed to those administered CCl4 alone.  The potential 
benefit to society as a result of this research is that aminophylline, which has already 
been approved by the Food and Drug Administration (FDA), could potentially be 
administered in the event of an overexposure to CCl4 or similar halocarbons to minimize 
  viii
the free radical-mediated hepatotoxicity resulting from overexposure. 
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Chapter One 
Introduction 
 
Statement of the Problem 
Carbon tetrachloride (CCl4) has been shown to cause hepatic centrilobular 
necrosis in humans and laboratory animals and the known mechanism of action for CCl4 
is thought to be free radical mediated and glutathione independent.   
It is hypothesized that the acute hepatotoxic effects of a wide variety of 
environmental pollutants and chemicals used in the workplace can be mediated by 
modulating the rate of poly ADP ribosylation.  Co-treatment or prior treatment of 
laboratory animals with a PARP inhibitor (e.g. 6(5H)-phenanthridinone or 
aminophylline) may reduce the acute hepatotoxicity produced by a variety of agents, 
particularly those with mechanisms of action that require free radical production. 
Specific Objectives 
Objective 1:  To determine whether the co-administration of aminophylline, a 
PARP inhibitor, significantly decreases the carbon tetrachloride-induced hepatotoxicity.  
Carbon tetrachloride was selected to be studied in this research because of the 
compounds ability to be used as a model for a number of compounds that have similar 
mechanisms of action.   
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  The specific aims of this objective include the following: 
Specific Aim 1:  To determine whether CCl4 induces liver damage using serum 
assays for alanine aminotransferase (ALT/GPT), aspartate aminotransferase 
(AST/GOT) and the thiobarbituric acid reactive substances (TBARS) hepatic 
tissue malondialdehyde assay. This will allow for the testing of the hypothesis 
that the co-administration of aminophylline reduces the acute toxicity of CCl4. 
Specific Aim 2:  To confirm the presence of CCl4-induced hepatotoxic effects via 
histopathologic examination techniques used on the livers extracted from mice, 
including hematoxylin and eosin (H&E), terminal deoxynucleotidyl transferase 
biotin-dUTP nick end labeling (TUNEL), and cleaved caspase 3.  These staining 
methods and evaluations are used in order to determine the extent of cellular 
damage. 
Objective 2:  To determine whether the co-treatment of aminophylline 
subsequent to CCl4 exposure significantly decreases the acute hepatotoxic effects of the 
model compound.   
 3
 
 
 
Chapter Two 
Literature Review  
 
Carbon Tetrachloride-Induced Hepatotoxicity 
Carbon tetrachloride (CCl4) is produced via the chlorination of a number of low 
molecular weight hydrocarbons.  For years, it was used as a dry-cleaning solvent, as well 
as in a number of consumer products for household cleaning and other purposes 
(ATSDR, 2005).  Since the gradual ban of CCl4, first from consumer products in the 
1990s, then from use as a dry-cleaning solvent, production has been dramatically 
reduced (ATSDR, 2005).  Because it is believed to be capable of depleting the ozone 
layer, CCl4 was one of the compounds to be phased out by 1996 as part of the Montreal 
Protocol, in which the United States and numerous other countries participated (den 
Elzen et al., 1992).  Prior to this phase out date, the United States Environmental 
Protection Agency divided the end product limits between the eight firms that were 
producing CCl4 in 1989.  Even with its elimination from consumer products, carbon 
tetrachloride is persistent in the environment, resulting in systemically absorbed dosages 
of approximately 0.1 µg/kg/day in a typical 70 kg adult who inhales 20 cubic meters of 
air per day.  (ATSDR, 2005).  Ironically enough, CCl4 is still being produced as a by-
product in the manufacture of perchlorethylene (tetrachloroethylene, Cl2C=CCl2), the 
 4
replacement of CCl4 as a dry cleaning solvent.  CCl4 is also released into the atmosphere 
as a product of the environmental decomposition of perchlorethylene (Singh et al., 1975). 
The primary toxicological effects of carbon tetrachloride are that two of its 
reductive metabolites produced by the CYP2E1 isoform of cytochrome P-450, the 
trichloromethyl radical (•CCl3) and the chlorine radical (•Cl) cause free radical damage 
to lipids, primarily in the cell and organelle membranes of hepatocytes.  (ATSDR, 2005).  
(Figure 1).  The former of these, •CCl3, is of particular concern, because of its rapid 
incorporation of oxygen to form the trichloromethyl peroxide radical (•OOCCl3).  The 
trichloromethyl peroxide radical can then interact with lipids (L), such as the 
phospholipids found in membranes, resulting in the formation of lipid peroxide radicals 
(LOO•), which can cause a chain reaction until it is terminated by binding to another 
radical, pairing their lone electrons.  This process of lipid peroxidation can significantly 
damage hepatic plasma membranes, that ultimately results in a necrotic response.  When 
trichloromethyl and chloride radicals interact with water they stabilize, forming 
chloroform (HCCl3) and hydrochloric acid (HCl), respectively (Recknagel, 1967).  
However, the residual product in both cases is •OOH (peroxy radical), a very reactive 
and harmful compound in its own right.  Other possible effects are damage to 
mitochondria and catecholamine-induced fatty liver and necrosis (Recknagel, 1967).   
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Figure 1: Mechanism of Carbon Tetrachloride-Induced Lipid Peroxidation.  Carbon 
tetrachloride is dehalogenated by cytochrome P450, resulting in two free radicals, the 
trichloromethyl radical and the chloride radical.  In the presence of oxygen, the 
trichloromethyl radical will bind and form a trichloromethylperoxy radical.  This radical 
and others can remove an electron from lipids, forming lipid free radicals.  These free 
radicals can then become peroxy radicals when in the presence of oxygen.  The lipid 
peroxy radicals can cause chain reactions until they are terminated by forming stable 
dimers with other free radicals.  Malondialdehyde (MDA), a lipid peroxy radical dimer, is 
a unit of measurement for the thiobarbituric acid reactive substances (TBARS) assay.  
Lipid peroxidation results in damage to cell and organ membranes.
 6
   There have been a number of in vitro studies that have associated CCl4 exposure 
with specific hepatocellular pathologic changes.  Two fairly recent studies have evaluated 
gene expression and other changes in response to CCl4 exposure (Harries et al., 2001, 
Holden et al., 2000).  Dai and Cederbaum (1995) determined that dosing HepG2 cells 
with 2mM CCl4 yielded a 30-50% decrease in cytochrome P4502E1 activity and levels.  
Beddowes et al. (2003) found elevated 8-oxodeoxyguanosine (8-oxodG) and 
malondialdehyde guanosine (M1dG) adducts and DNA strand breaks in HepG2 cells 
dosed with 4mM CCl4 and butathione sulfoxamine (BSO), which depletes reduced 
glutathione (GSH) levels. 
 Reduction of oxygen in the environment of male Wistar rats from 21% to 7% for 
the 24-hour interval commencing three hours prior to intraperitoneal administration of 0.1 
ml/kg CCl4 resulted in increases in the elevations of ALT and aspartate aminotransferase 
(AST) in the rats (Shibayama, 1986).  Hypoxia and CCl4 were each found to decrease 
arachidonic acid levels in the livers of male Sprague-Dawley rats, while palmitic, oleic 
and linoleic acid levels increased, suggesting that hypoxia potentiates CCl4 -induced 
hepatotoxicity, based on similar effects (Frank et al, 1987).  Increased binding of CCl4 
metabolites to hepatic microsomal proteins and lipids occurred at 12% oxygen versus the 
normal 21% in male rats (Shen et al, 1982).  Costa and Trudell (1989) strongly suggest 
that since the primary zone of CCl4-induced hepatic necrosis, the centrilobular area, has 
the lowest levels of oxygen, it is reasonable to assume that the low oxygen levels are a 
factor in this localization.  These studies run contrary to findings that singlet oxygen 
radicals were at lower levels in rats subjected to the oxygen equivalent of 4,400 m 
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altitude, as measured using in situ liver chemiluminescence (Costa et al, 1993).  
However, rats exposed to elevated concentrations of oxygen in conjunction with CCl4 
have increased survivability and diminished hepatotoxicity (Burkhart et al, 1991). 
The role of the sympathetic nervous system in the exacerbation of CCl4 -mediated 
hepatotoxicity has been thoroughly studied, and is believed to be a function of 
thermoregulation.  The reduction of the hepatotoxic effects due to CCl4 following spinal 
cord transection has been shown to vary based on the extent of the transsection, but only 
when the rats were kept at ambient temperature, and not incubated (Larson and Plaa, 
1963).  The degree of hepatoprotection decreased as the location of the spinal cord 
transsection was lowered from the 7th cervical vertebra to the 4th lumbar vertebra, and 
cervical cordotomy offered no protection against the early phases (3 hours) of oral dosage 
with 1.25 ml/kg CCl4 (Larson et al, 1964).  Cordotomized rats were found to develop 
lesions due to CCl4 much later (55-65 hours) than non-cordotomized rats, possibly due to 
the diminution by over 50% of oxygen consumption (Larson and Plaa, 1965).  
Immunological sympathectomy using antisympathetic nerve growth factor was 
ineffective against the hepatotoxic effects of CCl4 (Larson et al, 1964). 
 The hepatotoxic effects of CCl4 have also been documented following human 
exposures.  Although the most common route of exposure to CCl4 in humans is via 
inhalation, transdermal and oral routes of exposure may occur (ATSDR, 2005).  Despite 
efforts to phase out the use of CCl4 as a result of the Montreal Protocol, the National 
Institute for Occupational Safety and Health (NIOSH) has determined that approximately 
58,000 people in the United States still work with the hepatotoxicant (ATSDR, 2005).  
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As exposure to CCl4 via consumer products has greatly diminished, studies of 
occupational exposures and their impacts on the workers serve as a vital source of human 
toxicity data. 
The relative hepatotoxic effects of CCl4 in humans is greater than for similar 
haloalkanes, and is associated with necrotic, cirrhotic and steatotic hepatic lesions 
(Zimmerman and Lewis, 1995).  A 34-year-old man, who accidentally ingested half a 
mouthful of CCl4 recovered liver function, as determined by enzyme assays, within 15 
days, but his kidneys were unable to reabsorb water after 139 days (Alston, 1970).  
Increased radiographic density was found in the gastrointestinal tract of a 22-year-old 
man, who ingested approximately 12 ounces of CCl4 with the same amount of water, in a 
failed suicide attempt (Bagnasco et al, 1978). A seaman who used CCl4 to clean 
shipboard machinery was admitted to a hospital with nausea, vomiting, headaches and 
light- headedness, elevated heart rate and blood pressure; returning to normal liver 
function after artificial ventilation, peritoneal dialysis and other inpatient care for two 
weeks (Hadi and El Mikatti, 1981).  The use of CCl4 as a carpet cleaning solvent led to 
hepatoma in the resident five days later, with the patients reports of nausea, vomiting 
and anuria (Tracey and Sherlock, 1968).  Workers exposed to concentrations of CCl4 
above 1 ppm for periods ranging from less than 1 year to 5 years had significantly 
elevated levels of hepatic enzymes, but those exposed to lesser concentrations did not  
(Tomenson et al., 1995).  Chronic exposures to CCl4 may cause micronodular cirrhosis 
and hypertension of the portal system, which can arise decades after the exposure, as 
Gitlin (1980) found in an aircraft repairman exposed during the 1940s.   
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 A number of factors have been shown to exacerbate the hepatotoxic effects of 
CCl4 in laboratory animals, among them other xenobiotics and hypoxia.  Male and female 
ICR mice orally administered 2,5-hexanedione (15 mmol/kg) 18 hours prior to 
intraperitoneal administration of CCl4 (10 ul/kg) had 22-fold and 300-fold elevations in 
serum ALT relative to those lacking the pretreatment, respectively (Jernigan and 
Harbison, 1982).  Also, the 48-hour mean lethal dosage of CCl4 was decreased 67-fold in 
chlordecone-treated (10 ppm in diet) rats, versus 1.6-fold for phenobarbitol-treated (225 
ppm in diet) counterparts (Mehendale, 1984).  Kodavanti et al (1990) found that hepatic 
ATP levels in rats given intraperitoneal injections 100 µl/kg did not decrease 
significantly.  The same dosage in rats fed 10 ppm chlordecone resulted in reductions of 
31% and 81% at one and six hours, respectively.  Two catecholamines, epinephrine and 
norepinephrine, were found to potentiate CCl4-induced hepatotoxicity in mice, as 
evidenced by elevated ALT levels, whether administered concomitantly with, or six 
hours before or after CCl4 (Schwetz and Plaa, 1969).  Perhaps not surprisingly, 
intraperitoneal co-treatment of male ICR mice with 200 mg/kg phenylpropanolamine, 
which produces effects similar to catecholamines, potentiated the effects of 
intraperitoneal CCl4 dosages of 20-200 µl/kg (Roberts et al, 1991).  Concomitant 
intraperitoneal co-administration of rats with methamphetamine along with CCl4 
significantly increased the extent of liver injury, based on elevated ALT results, as well 
as histopathologic differences (Roberts et al, 1995b).  The mechanism for this 
potentiation was studied in mice, and is not believed to be linked to binding of CCl4 to 
proteins and  lipids, as it was not observed when methamphetamine dosage occurred 
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three hours following CCl4 (Roberts et al, 1995a).  Furthermore, the potentiation of CCl4-
induced hepatotoxicity was found not to be due to increased concentrations of chloroform 
(Roberts et al, 1994). 
There is reason to believe that ethanol may exacerbate the hepatic damage caused 
by CCl4, either through the increased activity of one or more metabolic enzymes or 
consumption of oxygen.  Wei et al (1971a, 1971b) found that ethanol, with or without 
induction of cold shock, can potentiate the hepatotoxicity of CCl4, as evidenced by 
elevated ALT levels.  Hasumura et al (1974) attributed the potentiation by ethanol to 
increased ornithine carbamyl transferase and ALT activity.  Co-treatment with ethanol is 
believed to exacerbate the hepatotoxic effects of CCl4, at least in part, as a result of 
decreased hepatic oxygen tension (Sato et al, 1983).  This decreased oxygen tension may 
be a result of the oxidative metabolism of ethanol, into acetaldehyde and ultimately into 
acetic acid. 
Deer et al (1987) assessed the concentrations of CCl4 resulting from grain 
fumigation, finding that all time-weighted average (TWA) exposures were well below 2 
ppm, averaging from 0.002 to 0.1 ppm, varying as a function on the type of task being 
performed.  These airborne concentrations of CCl4 were far below the Occupational 
Health and Safety Administration (OSHA) permissible exposure limit (PEL) TWA of 10 
ppm, and its ceiling of 25 ppm.  The usage of CCl4 as a fumigant was to be phased out in 
the United States pursuant the Montreal Protocol, due to its potential to deplete the ozone 
layer (den Elzen, 1992).  Despite this, CCl4 can be still used to create more complex 
compounds, since the Montreal Protocol was primarily focused on the end use or disposal 
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of these compounds.  As such, people working in proximity to chemical processes 
utilizing CCl4 may still be at some risk of exposure. 
 
PARP Inhibition 
Poly (ADP-Ribose) Polymerase-1 (PARP-1) (Enzyme Commission Number 
2.4.2.30) is an enzyme located in the nucleus, and becomes active in the presence of 
DNA damage.  PARP-1 binds nicotinamide adenosine dinucleotide (NAD+), and then 
affixes the adenosine diphosphateribose (ADP-ribose) moiety of NAD+ to a target 
protein or DNA.  Unlike Mono (ADP-ribosyl) Transferase (Enzyme Commission 
Number 2.4.2.31), which only adds one ADP-ribose moiety to the site of damage, PARP-
1 adds a chain of ADP-ribose moieties, with occasional side branches.  This process of 
polymerizing ADP-ribose onto a double strand DNA terminus can deplete the cell of 
NAD+.  As a result of this depletion, adenosine triphosphate (ATP), a critical energy 
storage compound, can become depleted as a result of diminished NAD+, possibly 
resulting in necrosis. 
 The activity of PARP-1 has been found to increase in the presence of DNA strand 
termini, responding to the likely double strand breaks.  N-methyl-N-nitro-N-
nitrosoguanidine (MNNG) is a compound that has been found to activate PARP-1, due to 
the ability of MNNG to cause DNA strand breaks, and serves as a positive control in 
PARP assays. 
It is hypothesized that the severity of acute hepatotoxic effects of a variety of 
environmental pollutants and chemicals in the workplace can be mediated by modulating 
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the rate of poly ADP ribosylation.  A number of compounds have been found to inhibit 
Poly (ADP-Ribose) Polymerase (PARP) (Banasik et al., 1992).  Ueda et al. (1995) 
reported that inhibition of PARP may play a role in initiating cellular differentiation.  It is 
hypothesized that the co-treatment or prior treatment of laboratory animals with a PARP 
inhibitor (e.g. 6(5H)-phenanthridinone) would reduce the acute hepatotoxicity of a 
number of compounds, particularly those with mechanisms of action that require free 
radical production.  A similar effect, as reported by Ueda, has been reported when PARP 
inhibitors were administered following cardiac reperfusion, to minimize the free radical-
mediated oxidative damage that often results.  Similarly, Ueda reported in a seminar 
(2003) that zonal necrosis often occurs at the site of myocardial infarctions (heart attacks) 
and could be minimized by the timely administration of a PARP inhibitor. 
Poly (ADP-ribose) polymerase, also known as PARP, poly (ADP-ribose) 
synthetase (PARS), is a critical enzyme that responds to DNA single-strand breakage.  
Although it can benefit cells at normal activity levels, excessive induction of PARP can 
deplete cells of the primary substrate for PARP, nicotinamide adenine diphosphate 
(NAD+) (Soriano et al., 2001).  NAD+ is necessary for ATP production, specifically for 
glycolysis and the electron transport chain.  In the absence of NAD+ and ATP, cells often 
undergo necrosis.  PARP is also believed to modulate nuclear factor kappa B activity and 
induce genes for inducible nitric oxide synthetase and intercellular adhesion molecule 1 
(Soriano et al., 2001).  As a result of these PARP-mediated changes, an inflammatory 
response ensues. 
 From their studies of PARP-1 knockout mice, Shall and de Murcia (2000) found 
 13
that PARP appears to play a critical role in the inflammatory response, as well as in the 
oxidative damage associated with reperfusion.  Mota-Felipe et al. (2002) used a battery 
of tests to evaluate the impact of the PARP inhibitor, 5-aminoisoquinolinone (5-AIQ), on 
reperfusion injury in male Wistar rats.  They found significantly lower increases in serum 
gamma-glutamyl transferase, lactate dehydrogenase, transaminases, as well as 
significantly lower amounts of  liver malondialdehyde, which is a measurement of lipid 
peroxidation, in rats treated with 5-AIQ. 
Another group of enzymes, mono (ADP-ribosyl) transferases, is similar to PARP 
in that they both utilize NAD+ and transfer ADP-ribose.  However, not only do they 
transfer a different number of ADP-ribosyl moieties, but they also target different amino 
acids and proteins (Banasik and Ueda, 1994). 
 Banasik et al. (1992) evaluated the effectiveness of a number of PARP inhibitors.  
They found four highly effective inhibitors, 4-amino-1,8-naphthalimide, 6(5H)- and 2-
nitro-6(5H)-phenanthridinones, and 1,5-dihydroxyisoquinoline, which had 50% 
inhibitory concentrations ranging from 0.18 to 0.39 µmol/l.  These concentrations were 
roughly two orders of magnitude greater than the comparable concentration for 3-
aminobenzamide.  Benzamide, a PARP inhibitor, has been shown to diminish the 
production of oxygen radicals by tumor promoter-activated neutrophils (Troll et al., 
1990). 
Other compounds and intracellular conditions may have lesser impacts on PARP 
activity.  Banasik and Ueda (1999) found that dimethyl sulfoxide is a biphasic inhibitor 
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of PARP at 37 °C, and is monophasic at 25 °C.  As with many other enzymes, the activity 
of PARP may be modulated by changes in pH, osmolarity, temperature and other factors. 
A number of PARP inhibitors have been shown to induce cell differentiation in 
murine teratocarcinoma EC cells, with a nearly complete change within one week (Ueda 
et al., 1995).  This ability to promote differentiation in an immortalized, nondifferentiated 
cell line may encourage further research on the anticancer potential of PARP inhibitors. 
 Rappeneau et al. (2000) exposed a human bronchial epithelial cell line 
(16HBE14o-) to mechlorethamine, a nitrogen mustard, to test the effectiveness of 6(5H)-
phenanthridinone and other PARP inhibitors.  These inhibitors were found to prevent the 
metabolic dysfunction found in cells only exposed to mechlorethamine. 
A study by Cole and Perez-Polo (2002) using PC12 cells, which model 
sympathetic neurons, showed that treatment with 3-aminobenzamide, a PARP inhibitor, 
significantly reduced the percentage of cells that died after hydrogen peroxide exposure. 
 Pacher et al. (2002) tested the efficacy of PJ34, a phenanthridinone-derivative 
PARP inhibitor, to reduce the cardiotoxic effects of Escherichia coli endotoxin 
(lipopolysaccharide).  Mice and rats that received both the endotoxin (55mg/kg) and the 
PARP inhibitor had increased survival and cardiac function than those that received the 
endotoxin alone.  Pacher et al. (2002) also tested the ability of PJ34 to reduce the 
cardiotoxicity of doxorubicin in BALB/c mice, finding improved cardiac function and 
survival, along with diminished serum creatine kinase lactate dehydrogenase activity 
levels.  Jagtap et al. (2002) performed a series of ex vivo analyses of the protective 
effects of PJ34 against oxidative damage associated with splanchic occlusion and 
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reperfusion in Balb/cmice.  Also administered was E. coli lipopolysaccharide (10 mg/kg) 
via intraperitoneal injection to Wistar rats.  PJ34 was found to reduce the production of 
inflammatory cytokines and chemokines in a dose-dependent fashion.  Liaudet et al. 
(2002) also used the same PARP inhibitor to determine whether E. coli 
lipopolysaccharide-induced lung inflammation could be minimized.  The BALB/c mice 
that received both lipopolysaccharide and PJ34 had lower levels of cytokines, 
chemokines, nitric oxide production, lipid peroxidation, neutrophil accumulation in 
alveoli, and excess lung permeability than mice that only received the lipopolysaccharide. 
The efficacy of two PARP-1 inhibitors, 6(5H)-phenanthridinone and benzamide, 
to reduce the development of experimental allergic encephalitis (EAE) in myelin-
immunized rats was evaluated by Chiarugi (2002).  These PARP inhibitors significantly 
reduced clinical score, neuroimmune infiltration, nitric oxide synthase, interleukin-1beta 
and -2, cyclooxygenase-2, tumor necrosis factor-alpha and interferon-gamma in the 
spinal cord, which are all associated with the development and progression of EAE.  Also 
there was no evidence of PARP-1 production, nor that of NAD(+) or ATP depletion, 
which can occur as a result of the substantial induction of PARP activity in these rats 
(Chiarugi, 2002). 
Aminophylline is a compound consisting of two molecules of theophylline, 
bridged by ethylene diamine.  Aminophylline is of medical importance, as it is water-
soluble, which allows for more versatile modes of administration, primarily via injection.  
Once aminophylline comes in contact with biological fluids, it disassociates into its 
constituents, two molecules of theophylline and one molecule of ethylene diamine.  The 
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Food and Drug Administration (FDA) has issued a fact sheet on aminophylline regarding 
its potential for adverse effects from its use in thigh creams, which they attribute to 
reports of allergic responses to ethylene diamine, a component in aminophylline.  
Aminophylline has a low therapeutic index, as is the case with theophylline.  As such, the 
doses which have been found to be efficacious anti-asthma remedies are not much lower 
than those associated with adverse health effects.  Fortunately, with the advent of 
aminophylline, it has become easier to titrate the dosage of aminophylline to one that is 
efficacious, yet lacking in adverse response.   
Theophylline (CAS # 58-55-9) is a naturally occurring methylxanthine alkaloid 
found in tea and chocolate, and is structurally similar to theobromine and caffeine (NTP, 
1998).  It was first isolated from tea by Albrecht Kossel in 1888, and was initially 
synthesized by Wilhelm Traube twelve years later.  Theophylline is administered to 
asthmatics to relax the smooth musculature of the bronchi, resulting in bronchial dilation 
and diuresis (NTP, 1998).  Theophylline can also stimulate the heart and the central 
nervous system via positive inotrophic (increased contractile force) as well as through 
positive chronotrophic (increased pulse) actions, resulting in elevated blood pressure 
(NTP, 1998).  Theophylline, a non-selective phosphodiesterase inhibitor, has been proven 
to be a highly effective inhibitor of the release of histamine from human basophils 
(Weston et al., 1997).  Given the common use of theophylline, and its similarity in 
structure to a number of other pharmaceuticals, the National Toxicology Program 
administered an array of tests to determine the potential for toxicological and/or 
carcinogenic outcomes in mice and rats (NTP, 1998).  There were no reports of 
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theophylline-induced carcinogenicity in humans (NTP, 1998).  Although there were some 
lesser findings (e.g. increased rates of uterine hyperplasia in female rats), no proof of 
carcinogenic action was seen as a result of theophylline in male and female F344/N rats 
administered up to 75 mg/kg of theophylline, nor in male or female B6C3F1 mice 
administered up to150 mg/kg and 75 mg/kg of theophylline, respectively (NTP, 1998).   
There have been many discoveries about the mechanism of action for 
theophylline, which is the functional unit and biologically active component of 
aminophylline.  Its structure resembles that of DNA and RNA purine bases (Cornish, 
1957).  As a result of this similarity, Bruns (1980) found that theophylline competes with 
adenosine for the nucleosides receptors, and results in ATP, ADP and AMP-induced 
increases in cyclic AMP (cAMP) levels.  This is important because of cAMPs role in 
cell signaling, potentially leading to apoptotic or necrotic responses.  Theophylline also 
functions as a non-specific phosphodiesterase inhibitor, distinguishing itself from newer 
phosphodiesterase-4 inhibitors (Boswell-Smith et al., 2006).  Another important 
mechanism of action associated with theophylline entails reversing the oxidation of 
histone deacetylase as a result of oxidative damage (Ito et al., 2002).  Theophylline 
activates histone deacetylases, which then suppress gene transcription, including those for 
inflammatory gene products (Barnes, 2005).  Theophylline works in conjunction with 
corticosteroids, which activate the glucocorticoid receptors, which are also critical to the 
suppression of inflammatory gene product transcription (Barnes, 2005).  This 
antioxidative mechanism may be a factor in preventing lipid peroxidation.  Yano et al., 
(2006) found that theophylline inhibits the conversion of pulmonary fibroblasts to 
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myofibroblasts by TGF-beta in COPD and asthma patients via cAMP and Protein Kinase 
A.  Theophylline also inhibits the production of collagen by suppressing its messenger 
RNA.  (Yano et al., 2006).  Huber et al., (2006) reported that theophylline, 200 mg 
administered via intravenous fluids 30 minutes prior to 100 ml of iodinated contrast 
medium, protected the kidneys, as evidenced by significantly lower serum creatinine 
levels, likely due to its adenosine receptor antagonism.  Last, but not least, theophylline 
(0.2, 1, 10 mM) significantly reduced the depletion of NAD+ caused by hydrogen 
peroxide (300 µM) in human lung epithelial cells(Moonen et al, 2005). This is attributed 
to the inhibition of PARP (Moonen et al., 2005). 
Theophylline can be metabolized by four distinct mechanisms.  Caffeine (1,3,7,-
trimethyl xanthine) can be demethylated in a reversible fashion to theophylline (1,3-
dimethylxanthine (Minton and Henry, 1996).  Subsequent irreversible demethylations can 
then occur at the 1 or 3 positions, yielding 3-methylxanthine or 1-methylxanthine, with 
the latter rapidly metabolized to 1-methyluric acid (Minton and Henry, 1996).  An 
alternate route of metabolism for theophylline involves its irreversible oxidation to 1,3 
dimethyluric acid.  Caffeine was the most common product of theophylline metabolism 
in explanted fetal livers, followed by 1,3-dimethyluric acid and 3-methylxanthine 
(Aranda, 1979).  The kinetics of metabolism is reported to be first-order at therapeutic 
levels, then becomes zero-order at higher levels once the enzymes become saturated 
(Minton, 1996).  Although this series of reactions is known to exist, additional factors can 
alter the metabolism of theophylline.  Theophylline has been found to bind to proteins in 
serum, thereby altering the pharmacokinetics (Ogilvie, 1978).  In an analysis of 47 
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patients treated with theophylline, Jacobs et al. (1976) found that there was little 
correlation between oral dosage of theophylline and its concentration in serum.  This 
makes it difficult for clinicians to titrate the appropriate dosage of theophylline, which is 
efficacious, yet does not cause any toxic effects. 
Theophylline has a low therapeutic index, in that the ratio between toxic dosages 
or levels and those that are efficacious is low (serum levels range from 10-20 µg/ml 
(Minton, 1996)). However, Jacobs et al (1976) reported gastrointestional symptoms of 
toxicity, such as nausea and vomiting, at levels as low as 15 µg/ml, which became more 
common at levels in excess of 25 µg/ml.  Non-gastrointestinal symptoms of theophylline 
toxicity included tremors at 26.4µg/ml, agitation at 28.5µg/ml, seizures at 39.9 µg/ml, 
and two patients with tachycardia at 46.3 and 49.5 µg/ml (Jacobs, 1976). 
A number of compounds can potentiate the toxic effects of theophylline.  Adult 
male rats which were pretreated intravenously with caffeine required significantly less 
theophylline, also administered intravenously, to induce seizures (Yasuhara, 1988).  This 
would appear self-explanatory, given the reversible conversion of theophylline to and 
from caffeine, with the presence of the latter shifting the equilibrium in favor of the 
former. 
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Figure 2.  Pathways of Theophylline Metabolism (Minton and Henry, 1996)
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Chapter Three 
Materials and Methods 
 There were several experimental procedures utilized to assess the level of damage 
induced by CCl4 and inhibited by inhibitors of (poly ADP-ribose) polymerase-1 (PARP-
1).  The differing nature of the in vitro and in vivo experiments allows for a division of 
this chapter into separate parts for in vitro and in vivo methodologies. 
 
In Vitro Methodologies 
All in vitro experiments were conducted using hepatocytes from a HepG2 cell line  
in the laboratory of Dr. Kunihiro Ueda at the Institute for Chemical Research at Kyoto 
University.  These hepatocytes were acquired by Dr. Kunihiro Ueda and Dr. Seigo 
Tanaka from the Rikken Laboratories in Japan.  The HepG2 cell line is derived from 
human primary hepatic cancer cells excised from a patient, and is widely utilized to 
assess the hepatotoxic effects of various compounds.   
The cell viability assay that was utilized to determine the proper dosage of 6(5H)-
phenanthridinone to protect the hepatocytes was the lactate dehydrogenase (LDH) 
cytotoxicity assay.  These cytotoxicity assays were used to determine whether 6(5H)-
phenanthridinone and other PARP inhibitors were protective against CCl4-induced 
hepatotoxicity.  LDH is an intracellular enzyme which, when found in the extracellular 
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milieu, is indicative of a loss of plasma membrane integrity.  The two phospholipid layers 
of the plasma membrane are susceptible to oxidative damage as a result of the 
trichloromethyl peroxide radical and other metabolites of CCl4.  The extent of cell 
mortality caused by a toxicant can be estimated by comparing the absorbance at 490 nm 
of the cell culture media for various treatment groups in comparison with a group treated 
with a lysis solution, which serves as a positive control. 
 After showing a reduction in LDH leakage into the cell culture media, PARP 
activity assays were conducted to determine whether the observed hepatoprotective effect 
of 6(5H)-phenanthridinone was related to the inhibition of PARP. 
 
Cytotoxicity Assays 
In order to determine whether the co-treatment with 6(5H)-phenanthridinone is 
beneficial to the hepatocytes, LDH concentrations in cell media were measured using a 
colorimetric assay (Promega, Madison, WI, USA).  Samples containing 2 x 104 HepG2 
cells in 200 µl of Eagle minimal essential media (1 x105 cells/ml) HepG2 cells were 
resuspended and transferred to each of 48-well plates in 200 µl of Eagle minimal 
essential media per well.  The media was treated with the appropriate concentrations of 
CCl4 ranging from five to twenty millimoles per liter (mM), and 6(5H)-phenanthridinone 
ranging from ten to forty micromoles per liter (µM).  Each treatment combination was 
tested in triplicate on 48-well plates, with triplicate blanks, which contained treated 
media, but no HepG2 cells.  The well plates were incubated at 37°C for a period of 
twenty-four hours prior to the start of the assay.  The positive control was established via 
the administration of 20µl of the 10x cell lysis solution provided with the assay reagents 
 23
two hours prior to the assay in wells with previously untreated cells.  The supernatants 
were drawn from each of the wells and centrifuged at 250g for four minutes, and 50 µl of 
each supernatant was placed in its corresponding well on a 96-well plate.  Fifty 
microliters of a sample buffer containing NAD+ and lactate, substrates for lactate 
dehydrogenase, were added and then the well plate was incubated in a closed drawer for 
thirty minutes.  After the incubation period expired, 50 µl of the stop solution was added 
to each well, and the well plate analyzed.   The absorbance readings were taken using a 
Bio-Rad Model 550 microplate reader (Hercules, CA, USA) at a wavelength of 490 nm.   
 
PARP Activity Assays 
In order to determine whether the activity of PARP-1 is modulated by the 
administration of CCl4 and/or 6(5H)-phenanthridinone, an in vitro assay involving the 
incorporation of radiolabeled NAD+ into poly-ADP ribose was utilized.  HepG2 cells 
were cultured to a minimum of 50% confluence on 60 mm glass cell culture dishes.  
Duplicate treatments with CCl4 and/or 6(5H)-phenanthridinone were conducted via 
dilution in 5 ml of cell culture media, sonication, then replacement of the previous cell 
culture media with the appropriate treatment.  Culture dishes were returned to the 
incubator following the change of media.  Upon completion of the exposure interval, the 
cell culture dishes were removed from the incubator.  After the cells were scraped from 
each of the culture dishes and pipetted into its own 50 ml centrifuge tube, each of these 
dishes was washed with 5 ml of phosphate buffered saline (PBS, pH 7.2), which was also 
pipetted into the appropriate centrifuge tube.  These tubes (kept on ice) were 
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subsequently centrifuged at 3,000 revolutions per minute (rpm) for five minutes at 4 ºC.  
Digitonin, which is used to perforate the nuclear and plasma membranes of the HepG2 
cells, was administered at 0.005% in PBS at 4 ºC.  The pellets were resuspended in 1.00 
ml of 0.005% digitonin, transferred to microcentrifuge tubes, and then kept on ice for 3 
minutes.  Following this interval, the microcentrifuge tubes were centrifuged at 6,000 
rpm for 5 minutes at 4 ºC.  After the supernatant was removed, the pellets were 
resuspended in 1.00 ml of PBS, which allowed for the cells to be counted.  The numbers 
of cells were equalized by resuspending the cells, then removing the proportionate 
volume of PBS and cells.  After this, the microcentrifuge tubes were spun once again at 
6,000 rpm for 5 minutes at 4 ºC.  The supernatants were removed from the 
microcentrifuge tubes, and the pellets were kept on ice.  The reaction mixture for this 
assay was partially prepared in a 50 ml centrifuge tube, and consisted of 190 µl of 
reaction buffer and 5 µl of 10 mM NAD per sample, plus two additional volumes of each, 
one for the background reading and one to ensure the transfer of the entire volume from 
the centrifuge tube to each sample.  The remaining 5 µl of carbon-14 radiolabeled NAD 
(0.1 uCi Adenosine 14C NAD) per sample (with two additional aliquots) was added in the 
radioisotope laboratory.  This reaction mixture was mixed and kept on ice until used.  
The samples were individually resuspended in the reaction mixture and were placed in a 
30 ºC bath for 5 minutes, to allow for the formation of poly-ADP ribose.  This kinetically 
based reaction was halted by the addition and pipette-based mixing of 800 µl of ice-cold 
(0-4ºC) 25% trichloroacetic acid (TCA).  The samples were placed on ice for 30 minutes.  
The samples were then vacuum-filtered using methylcellulose membranes and washed 
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thrice with 3 ml of 5% TCA.  The membranes were dried under heat lamps for 30 
minutes.  After that, they were placed in liquid scintillation vials containing 5 ml of 
scintillation fluid.  These vials were counted for carbon-14 over 5 minute intervals.  The 
resulting counts per minute for each sample were indicative of the activity of PARP. 
 
In Vivo Methodologies 
 All of the animal experiments were performed in accordance with the animal 
welfare guidelines established by the Division of Comparative Medicine, University of 
South Florida Office of Research.  The Division of Comparative Medicine has been fully 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC).  The National Research Council devised the Guide for the Care and 
Use of Laboratory Animals, which has also been the basis of many of the policies, along 
with the FDA Good Laboratory Procedures. 
 The male ICR mice were housed at the vivarium at the USF College of Public 
Health for a period of no fewer than seven days to allow for them to become acclimated.  
Prior to being sacrificed, the mice received tap water and food (Harlan Rodent Chow, 
2018) ad libitum.  Male mice were selected exclusively for these experiments to eliminate 
the potential for variation as a result of murine ovulatory and hormonal cycles. 
Each of the mice was weighed prior to dosing to ensure the proper dosage was 
administered.  Since the toxicant used in these experiments, CCl4, was dissolved in corn 
oil and the co-treatments; 6(5H)-phenanthridinone, benzamide, nicotinamide and 
aminophylline, were dissolved in saline (with dimethyl sulfoxide in the case of 6(5H)-
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phenanthridinone), two separate injections were required. Control mice were 
administered injections with both solvents, and mice receiving either the toxicant or the 
co-treatment were administered the solvent for the other treatment.  This process of 
injecting the vehicle for mice not receiving the toxicant and/or co-treatment is performed 
to ensure that any difference in effects observed in the mice, their serum and tissue assays 
and the liver histopathology from the treatments would have to be a function of the 
chemicals themselves, and not from the injections.  The injections have the potential to 
cause inflammatory responses to the peritoneal cavity and skin, as a result of the tearing 
of the skin by the needle and the introduction of bacteria and other flora/fauna from the 
fur and surface of the skin into the peritoneal cavity.  This can be further exacerbated by 
the introduction of bacteria to the site of injection through scratching or biting by the 
mouse that was injected, or by other mice in the same cage.  The impact of the injections 
were minimized by utilizing tuberculin syringes with 25 gauge needles and by replacing 
them frequently, to ensure that the edges the needles are sufficiently sharp.  Following the 
intraperitoneal injection of the appropriate treatment regimen, the abdominal fur of each 
mouse was inspected to confirm that the entire dosage was delivered, and did not seep out 
of the site of the needle puncture. 
Upon the completion of the treatment duration, the mice were euthanized via 
simple asphyxiation with carbon dioxide.  As a result of this process, the mice underwent 
respiratory arrest, during which time the blood became aggregated in the heart and the 
lungs.  Blood was taken from mice via cardiac puncture with a 1 ml tuberculin syringe 
with a 25 gauge needle.  Then, with the needle removed, the blood was slowly expelled 
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from the syringe into a 1.5 ml microcentrifuge tube.  Under optimal conditions, the 
volume of blood collected per mouse ranged from 0.7 to 1.0 ml.  After waiting for a 
period of 10 minutes, the blood was centrifuged at 6,000 x g for 10 minutes.  Following 
centrifugation, the supernatant (serum) from each microcentrifuge tube was transferred to 
its corresponding serum sample microcentrifuge tube using a 200 µl micropipetter.  
Following the collection of the serum samples, they were stored at 4 ûC for less than two 
days prior to being assayed, to minimize the potential for degradation. 
In summation, Male ICR mice (Harlan, Indianapolis, IN) were housed and 
handled in accordance with AAALAC guidelines.  Mice were randomized into four 
groups, receiving either CCl4 (0.025 ml/kg, Sigma-Aldrich, St. Louis, MO) in corn oil or 
corn oil via intraperitoneal (IP) injection, with total volumes of 150 µl.  At intervals of 
30, 60, and in some experiments 120 minutes following the toxicant, mice were injected 
with 150 µl of aminophylline (50 mg/kg, Sigma-Aldrich) in PBS or saline.  Mice were 
sacrificed after 24 hours, so that the blood and liver tissue could be collected.  Serum 
ALT was assayed with an endpoint colorimetric assay (Teco Diagnostics, Anaheim, CA).  
Liver samples were homogenized 10:1 in saline, and the homogenates were assayed for 
lipid peroxidation, in malondialdehyde equivalent concentrations, using the thiobarbituric 
acid reactive substances (TBARS) assay (Northwest Life Science Specialties, Vancouver, 
WA).  Liver samples were also collected in formalin and encased in paraffin for 
histopathhologic analysis.  The procedures used were hematoxylin and eosin H&E 
staining, terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) 
assay and caspase-3 immunohistochemistry.  One way ANOVA was used to assess the 
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significance of differences, with p-values below 0.05 indicative of significant differences. 
 
Serum ALT/AST Assays 
Two of the most efficient methodologies available to evaluate the extent of the 
CCl4-induced hepatocellular damage are the colorimetric endpoint assays for ALT and 
AST.   Other assays are available, however personal experience with some of the kinetic 
assays suggests that sera from mice with extensive hepatocellular damage may be 
difficult, if not impossible to use.  The assay reagents (Teco Diagnostics, Anaheim, CA) 
were utilized to produce, an endpoint reaction, which can be detected in the visible light 
spectrum, as previously reported by Reitman and Frankel (1957).  The substrate solution 
consisted of 0.2 M L-alanine, 2.0 mM alpha-ketoglutaric acid, 100 mM phosphate buffer 
at pH 7.4 and 0.2% preservatives.  A portion of the L-alanine from the substrate was 
converted to pyruvate, and the alpha-ketoglutaric acid was converted to glutamic acid.  
The resulting pyruvate was subsequently reacted with a color reagent consisting of 1.0 
mM 2,4-dinitrophenylhydrazine in 1 N hydrochloric acid,  to yield 2,4-
dinitrophenylhydrazone.  This red-colored product absorbs visible light, with a maximum 
absorbance at 505 nm.   
The substrate solution was transferred in 250 µl aliquots via micropipette into 
labeled microcentrifuge tubes.  The serum samples were removed from storage at 4ºC 
and centrifuged at 6,000 x g for ten minutes at ambient temperature, to ensure that any 
erroneously transferred erythrocytes or other materials are relegated to the bottom of the 
microcentrifuge tubes prior to removal of aliquots for the assay.  After warming the 
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substrate in a 37 ºC water bath for three to five minutes, 50 µl of serum was transferred to 
the corresponding tube for each sample.  A reagent blank was also prepared, along with a 
standard, in which 50 µl of a 70 IU/ml standard was used in lieu of serum.  The original 
microcentrifuge tubes containing serum were returned to storage at 4 ºC, and those 
containing the substrate solution and serum or standard were mixed and incubated at 
37ºC for a period of 30 minutes along with the reagent blank.  Following this interval, 
250 µl of color reagent was added to each microcentrifuge tube, and the samples were 
once again mixed and returned to the 37 ºC water bath for a ten minute incubation period.  
After the ten minutes elapsed, 1.00 ml of the color developing solution was added to each 
microcentrifuge tube, which was subsequently mixed and returned to the water bath for 
five minutes.  After this interval, the samples were transferred to disposable semi-micro 
cuvettes, which were placed into a UV/Visible spectrophotometer, and the absorbances 
were recorded at a wavelength of 505 nm.  
 
TBARS Assays 
 After the mice were euthanized, their livers were removed and placed in 50ml 
centrifuge tubes on ice and subsequently frozen at -70 °C until they could be 
homogenized and assayed.  The livers were homogenized in a 1:10 weight to volume 
proportion in cold PBS (Fisher Scientific, Pittsburgh, PA) and returned to the -70 °C 
freezer until the assays were conducted.  The TBARS assay (Northwest Life Science 
Specialties, Vancouver, WA) provided a saline buffer for this purpose, but its volume 
would have been insufficient for the requisite dilutions, so the PBS from the above 
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supplier was utilized in lieu of the one provided. 
 Microcentrifuge tubes were labeled for the standards and the samples.  Ten µl of 
butylated hydroxytoluene (BHT) was added to each tube, followed by 250 µl of the 
standard or liver homogenate, 250 µl of 1 M phosphoric acid and 250 µl of thiobarbituric 
acid (TBA) solution (TBA in 10.5 ml deionized water).  The tubes were closed and 
mixed with a vortex mixer for five seconds, and then incubated at 60 °C on a dry bath 
(Fisher Scientific, Pittsburgh, PA) for one hour.  The tubes were then centrifuged at 
10,000 x g for three minutes, and the absorbance readings were taken at 572 nm.  The 
absorbance readings for the standard concentrations (in MDA equivalents) were used to 
create a standard curve, which was used to determine the levels of MDA equivalents for 
the homogenates.  These results were then multiplied by 11, to account for the 1:10 
dilution, to determine the final concentrations of MDA equivalents. 
 
Histopathologic Staining / Immunohistochemistry   
Livers were preserved in 10% neutral buffered formalin (Fisher Scientific, 
Pittsburgh, PA).  The livers were sectioned (5 - 6 mm), dehydrated with ethyl alcohol, 
cleared with xylene and embedded in paraffin.  Sections of 5- to 6-mm were mounted, 
dried and stained with hemotoxylin/eosin to assess parenchymal histopathological 
changes.  The methodology used to evaluate hepatotoxicity has been described previously 
(Price et al., 1999).  Briefly, the parameters evaluated were proliferation, apoptosis, 
necrosis and fibrosis.  Proliferation was determined according to the presence of four 
parameters:  hepatocyte hyperplasia, hepatocyte hypertrophy, mitotic activity and 
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binculeation.  To determine proliferation intensity, the sum of the individual intensity of 
each of the four parameters was used to reach a total score of no observable pathological 
changes (0), mild intensity (1), moderate intensity (2) or prominent intensity (3). 
Apoptosis was evaluated by using ApopTag® Plus In Situ Apoptosis Detection, 
according to a standard protocol.  This method allows for visualization of apoptotic 
bodices and also intact apoptotic nuclei.  It is a useful method for detecting apoptosis at 
the earliest stages.  A solid brown nuclear staining identified apoptotic hepatocytes.  The 
number of apoptotic cells was expressed as a percentage of total number of cells 
(Apoptotic Index, AI).  The AI was then converted to a numerical score.  No observable 
apotosis is given a score of zero, and this equates to AI 0%; mild intensity is given a 
score of 1, and represents AI <25%; moderate intensity is given a score of 2, and 
represents AI 25% to 50%; prominent intensity is given a score of 3, and  represents AI 
50%. 
Cleaved Caspase-3 histopathology was performed using Cleaved Caspase-3 
(Asp175) (5A1) Rabbit Monoclonal Antibody from Cell Signaling Technology.  The 
method of immunochemistry was used.  Cleaved caspase-3 (Asp175) detects levels of 
large fragments (17-19 kDa) of activated caspase-3 resulting from cleavage adjacent to 
Asp175.  Expression of cleaved caspase-3 stains a deep red to brown in color.  The scale 
for expression is 0 to 4.  A score of 0 is no expression of cleaved caspase-3.  A score of 1 
is <25% of the centrilobular region expressing cleaved caspase-3.  A score of 2 is 26-50% 
expression.  A score of 3 is 51-75% expression.  A score of 4 is 76-100% expression.  
The cleavage of caspase-3 is a step in the apoptotic response which commits cells to 
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programmed cell death.
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Chapter Four 
Results 
The results of these experiments strongly suggest that the administration of CCl4 
causes hepatocellular damage.  This is evidenced in the significant increases in LDH 
levels and PARP activity in a human cell line (HepG2), as well as in the increases in 
ALT, lipid peroxidation, and the histopathological findings of necrosis and apoptosis in 
ICR mice.  The use of 6(5H)-phenanthridinone or aminophylline significantly reduced or 
blocked these adverse effects to the liver.  This suggests that PARP inhibitors may play a 
role in protecting the liver against the effects of carbon tetrachloride, a free radical-
mediated, glutathione-independent hepatotoxicant. 
The findings from these experiments are divided into the subcategories of in vitro 
and in vivo assay results and other relevant findings.  The in vitro experiments conducted 
yielded the following assay results: lactate dehydrogenase (LDH) and poly (ADP-ribose) 
polymerase (PARP) activity.  The in vivo experiments yielded results derived from 
assays for two analytes: alanine aminotransferase (ALT) and thiobarbituric acid reactive 
substances (TBARS).  The in vivo experiments also yielded the following: 
histopathological stains using hematoxylin and eosin (H&E) and terminal 
deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL), and 
immunohistochemistry for the cleaved form of caspase-3.  These tests were utilized in 
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conjunction with one another, using the same mice.  For example, by using the serum for 
ALT and divided liver for histopathology and TBARS, I was able to gather the maximum 
amount of phenomenological data per experiment. 
 
In Vitro Results 
Data from preliminary in vivo experiments conducted in the laboratory suggested 
that the hepatotoxicity induced by CCl4 in male ICR mice can be attenuated via the use of 
6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase (PARP).  The 
levels of glutamic oxalacetic transaminase (GOT) and glutamic pyruvic transaminase 
(GPT), two hepatocellular enzymes, in the serum samples were significantly lower in 
mice receiving both  carbon tetrachloride and 6(5H)-phenanthridinone, than in those only 
treated with carbon tetrachloride.  Also, there were dramatic histopathologic differences 
in liver samples from carbon tetrachloride-treated mice, between those receiving 6(5H)-
phenanthridinone as a co-treatment, and those that did not.  Hematoxylin and eosin 
staining revealed severe centrilobular necrosis in mice receiving only carbon 
tetrachloride, and normal morphology in those also administered 6(5H)-
phenanthridinone.  TUNEL staining, which was used to detect apoptosis, revealed 
numerous centrilobular hepatocytes undergoing apoptosis in mice treated solely with 
carbon tetrachloride, but not in mice receiving both treatments. 
As a result of these in vivo experiments, there was an interest in determining whether 
PARP is directly involved in the attenuation of this hepatotoxicity, or perhaps some other 
aspect of the co-treatment with 6(5H)-phenanthridinone may play a role in its 
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hepatoprotection.  One possible alternative explanation for the reduction in carbon 
tetrachloride-induced hepatotoxicity is the inhibition of various cytochrome p450 CYP 
isoforms by substituted phenanthridinone compounds.  Competitive binding assays using 
tritium-radiolabeled 2,3,7,8-tetrachlorodibenzo-p-dioxin as a substrate revealed 50% 
inhibition of cytochrome P450 activity at concentrations of 317 to 5870 nM for a variety 
of 2-substituted phenanthridinones (Liu et al., 1994).  Also, dimethyl sulfoxide (DMSO) 
can have an inhibitory effect on the activity of various isoforms of cytochrome P450 
(CYP), most notably an 89% inhibition of CYP2E1 at 1% DMSO (Easterbrook, Lu et al. 
2001).  CYP2E1 is the isoform of cytochrome P450, which is primarily responsible for 
the bioactivation of carbon tetrachloride to the trichloromethyl radical (CCl3).  This 
trichloromethyl radical can spontaneously combine with oxygen, yielding the 
trichloromethyl peroxy radical (OOCCl3).  This and subsequent radicals are believed to 
be responsible for the resulting lipid peroxidation and microsomal damage (Rao and 
Recknagel, 1968). 
The two assays performed on the HepG2 cells using 6(5H)-phenanthridinone and 
benzamide as PARP inhibitors were utilized to determine whether there was damage to 
the hepatocytes, as well as whether PARP was involved.  These tests involved the 
presence of LDH, an intracellular enzyme, in the cell culture media, and the activity of 
PARP, as evidenced by the conversion of carbon-14 radiolabeled NAD into poly(ADP-
ribose).   
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Ctyotoxicity Assays 
 The cytotoxicity assay was used to determine the viability of the cells in general, 
and the structural integrity of the hepatic cell membranes in particular, following 
exposure to CCl4.  Because LDH is an intracellular enzyme, when it is present in the cell 
culture media, it suggests that the free radical-mediated damage caused by CCl4 was 
sufficient to let this enzyme escape the cells.  The following tables and charts suggest that 
PARP inhibitors can reduce this damage to the hepatocytes.  These data also suggest that 
the extent of damage to the hepatocytes increases with the concentration of CCl4.  The 
LDH levels were not, however, established as absolute concentrations and, since the 
numbers of cells may not have been identical between experiments, the results were only 
relative indications of the extent of loss of membrane integrity and/or death of the 
hepatocytes.  The use of a positive control, cells exposed to the cell lysis solution, can 
help determine the extent of the cytotoxicity.   
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Table 1: Percent Cytotoxicity at Varied PARP Inhibitor Levels.  The results are expressed 
as percent cytotoxicity, as determined by the ratio of absorbances at 490 nm for the cell 
culture media for each sample in comparison to the mean result for the positive control 
group, in which the cells were exposed to the lysis solution.  The data are presented in 
Figure 3. 
  Percent Cytotoxicity, HepG2 Cells       
  
Sample 
1 
Sample 
2 
Sample 
3 Average 
Std 
Dev Std Err Ttest 
Control 3.85164 22.5755 18.6104 15.013 9.8668 5.69662   
0.2% DMSO 6.84736 
-
3.02067 12.2829 5.3699 7.758 4.47910   
DMSO+20uM Phen 6.84736 3.6566 3.84615 4.7834 1.79 1.03344   
DMSO+40uM Phen 9.84308 2.54372 2.8536 5.0801 4.1277 2.38315   
DMSO+1mM BA 12.2682 25.2782 
-
5.58313 10.654 15.494 8.94537   
DMSO + 10mM CCl4 51.3552 59.3005 50 53.552 5.0243 2.90079   
DMSO + 10mM CCl4 + 20uM 
Phen 20.97 32.5914 21.7122 25.091 6.506 3.75622 0.00070 
DMSO + 10mM CCl4 + 40uM 
Phen 6.84736 4.45151 11.5385 7.6124 3.6049 2.08128 0.00534 
DMSO + 10mM CCl4 + 1mM 
BA 28.388 26.868 0 18.419 15.969 9.21979 0.02362 
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Figure 3: Percent Cytotoxicity at Varied PARP Inhibitor Levels.  Cytotoxicity assay data 
for hepatocytes exposed to 10 mM CCl4 and 6(5H)-phenanthridinone (10 mM CCl4+20 
µM Phen, 10 mM CCl4+40 µM Phen) and 10 mM CCl4 and 1 mM benzamide (10 mM 
CCl4+1mM BzAm) compared to those exposed to 10 mM CCl4 only (10 mM CCl4).  
Results are expressed as mean ± SEM.  One-tailed Paired T-tests were performed with * 
indicating a significant difference at p<0.05 and ** indicating a significant difference at 
p<0.01.   
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The results of this experiment address two critical issues, the adverse impact of 
CCl4 on the human liver cells, and the possibility of this deleterious impact being 
lessened by phenanthridinone, a specific PARP inhibitor.  The addition of 10 mM CCl4 
and 0.2% DMSO to the culture media resulted in nearly ten-fold elevations in the level of 
LDH in the culture media.  The impact of this finding on the condition of the hepatocytes 
is important, because LDH is an intracellular enzyme that should not be found outside the 
cells, and elevated levels of LDH outside the cells are indicative of damage to the plasma 
membranes.  The loss of plasma membrane integrity can be irreversible; as such the LDH 
assay is often used to assess the extent of cell viability.  The extent of membrane damage 
to the hepatocytes can be estimated as a function of the findings for the positive control 
lysis buffer solution, which is believed to result in complete lysis of the hepatocytes.  As 
such, if one assumes the linearity of the LDH assay, roughly fifty percent of the 
hepatocytes incurred plasma membrane damage as a result of the introduction of 10 mM 
CCl4 to the cell culture media.  It appears that the co-administration of 6(5H)-
phenanthridinone mitigates this cell membrane damage. 
The CCl4-mediated increase in LDH in the cell culture media was significantly 
reduced (p<0.01) by the addition of 20 or 40 µM 6(5H)-phenanthridinone, however in the 
case of the former, the LDH levels were still triple those found when only 0.2% DMSO 
was added to the media.  Although it is unclear as to whether the resulting LDH levels in 
the cell culture media when 20 µM 6(5H)-phenanthridinone and 10 mM CCl4 were 
administered, were indicative of irreversible damage to the hepatocytes. However, one 
can assume that the presence of 6(5H)-phenanthridinone in the media is hepatoprotective 
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against CCl4mediated hepatocellular damage. 
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Table 2: Percent Cytotoxicity with Varied Carbon Tetrachloride Levels.  The results are 
expressed as percent cytotoxicity, as determined by the ratio of absorbances at 490 nm 
for the cell culture media for each sample in comparison to the mean result for the 
positive control group, in which the cells were exposed to the lysis solution.  These data, 
which are presented in Figure 4, suggest that these higher concentrations of carbon 
tetrachloride produce hepatocellular damage comparable to the lysis solution, which was 
used to maximize cell death. 
  Percent Cytotoxicity, HepG2 Cells   
  
Sample 
1 
Sample 
2 
Sample 
3 Average Std Dev Std Err T-Test 
Control 2.26077 2.06124 1.61544 1.97915 0.3304 0.19076   
0.2% DMSO 12.6198 17.1946 12.7379 14.1841 2.60781 1.50562   
0.2%DMSO + 20mM 
CCl4 138.339 103.922 132.65 124.97 18.4491 10.6516 0.00590 
0.2%DMSO +40mM CCl4 75.2396 68.4766 86.3836 76.6999 9.04237 5.22061 0.00525 
0.2%DMSO + 80mM 
CCl4 101.757 80.9955 109.37 97.3744 14.6864 8.47922 0.00698 
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Figure 4: Percent Cytotoxicity at Varied Carbon Tetrachloride Levels.  Cytotoxicity assay 
data for hepatocytes exposed to 20 mM CCl4 , 40 mM CCl4, and 60 mM CCl4 compared 
to those exposed to the DMSO controls.  Results are expressed as mean ± SEM.  One-
tailed Paired T-tests were performed with ** indicating a significant difference at p<0.01.   
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The purpose of the previous study was to assess whether the hepatocellular 
plasma membrane damage caused by CCl4 was maximized at 10 mM, or whether higher 
concentrations could produce even more cell lysis.  The extent of cell membrane damage 
is estimated by assaying for the presence of LDH in the cell culture media, as evidenced 
by the absorbance of visible light with a wavelength of 490 nm, which is due to the 
dehydrogenation of lactate to pyruvate and the reduction of NAD+ to NADH.  When 
compared with the LDH assay results for wells where the lysis buffer was used as a 
positive control, the incorporation of higher concentrations of CCl4 into the cell culture 
media resulted in LDH levels comparable to those for the lysis buffer.  The ratio of 
absorbance measurements at 490 nm for 10 mM CCl4 versus the lysis buffer in the 
previous experiment was roughly 0.5, whereas in this latter experiment, the higher 
concentrations of CCl4 in the cell culture media approximated a ratio of 1 to 1.  It was 
unclear from subsequent experiments as to whether 6(5H)-phenanthridinone could 
consistently and significantly protect against this more extensive hepatocellular damage. 
 
PARP Activity Assays 
 PARP activity assays were conducted to determine if the protection provided by 
6(5H)-phenanthridinone is directly related to the inhibition of PARP, or whether some 
other mechanism is the cause.  There is a direct correlation between the intensity of 
exposure to CCl4, in terms of concentration or duration of exposure, and PARP activity, 
given there are enough viable cells to proceed with the assay.  N-Methyl-N'-Nitro-N-
Nitrosoguanidine (MNNG), a known mutagen, was administered to serve as a strong 
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positive control for PARP activity.  Incubation in media treated only with DMSO, the 
solvent in which 6(5H)-phenanthridinone is dissolved, was used as a baseline in the 
absence of PARP-inducing compounds.  Although DMSO has been reported to inhibit 
PARP, the level of inhibition at this low concentration is assumed to be insignificant, thus 
it did not impact the results.  These findings strongly suggest that the increase in PARP 
activity due to MNNG and CCl4 is largely attenuated by 6(5H)-phenanthridinone, giving 
insight into the mechanism by which it protects the hepatocytes.   
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Table 3: PARP Activity With and Without 6(5H)-Phenanthridinone Co-treatment.  
6(5H)-phenanthridinone reduces increases in PARP activity caused by N-Methyl-N'-
Nitro-N-Nitrosoguanidine (MNNG), a known mutagen which serves as a positive control.  
PARP activity is assessed relative to the polymerization of carbon-14 radiolabeled NAD+ 
into poly (ADP-ribose).  These results are expressed as multiples of the DMSO controls 
in Figure 5. 
PARP Activity Assay, HepG2 Cells 1.70x10^6 cells/sample 
MNNG 2 hr. exposure   5 min. count time   
Treatment 
14C CPM 
#1 
14C CPM 
#2 Blank CPM 
Avg. 
Diff. 
0.2% DMSO, 4 hr. 2104.6 3122.2 900.8 1712.6 
200 uM MNNG + 0.2% 
DMSO 37672.2 46513.6 900.8 41192.1 
MNNG + DMSO + 40 uM 
Phen 4098 3674.8 900.8 2985.6 
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Figure 5: PARP Activity With and Without 6(5H)-Phenanthridinone Co-treatment.  One-
way Paired T-tests were performed between MNNG and MNNG + 6,(5H)-
phenanthridinone.  Results are expressed as mean ± SEM.  One-tailed Paired T-tests were 
performed with * indicating a significant difference at p<0.05.  This proves the 
hypothesis that 6,(5H)-phenanthridinone can protect against the overactivation of PARP 
caused by this known mutagen and PARP inducer.  
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The results from this PARP activity assay indicate that 6(5H)-phenanthridinone 
(40 µM) can significantly reduce the effects of MNNG, a known mutagen.  The PARP 
activity, as evidenced by the counts of carbon-14 radiolabeled NAD+ that were 
polymerized into poly ADP-ribose.  Unlike the radiolabeled NAD+, which would have 
passed through the pores in the methylcellulose membranes during the sample washings, 
the polyADP-ribose would not have done so, and as such it remained present on the 
membranes and resulted in the elevated carbon-14 counts.  The counts of carbon-14 were 
much higher in this experiment than in the previous one, most likely because a new 
aliquot of carbon-14 radiolabeled NAD+ was used in this experiment. 
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Table 4: PARP Activity With 6(5H)-Phenanthridinone and Carbon Tetrachloride.  The 
increases in PARP activities associated with CCl4, as evidenced by increased carbon-14 
activities from the incorporation of radiolabeled NAD into poly (ADP-ribose), were 
diminished by 40 µM 6(5H)-phenanthridinone.  This indicates that 6(5H)-
phenanthridinone prevents the over activation of PARP, which can result in cell death by 
necrosis, due to a lack of cellular energy.  The results are expressed as multiples of the 
DMSO control in Figure 6. 
PARP Activity, HepG2 Cells, 1.255x10^6 cells/sample     
    5 min. count time   
Treatment 
14C CPM 
#1 
14C CPM 
#2 
Blank 
CPM Avg. Diff. 
0.2% DMSO, 4 hr. 977.8 832.8 161.6 743.7 
0.2% DMSO + 40uM Phen, 4 hr. 302.6 1096.2 161.6 537.8 
DMSO + 20mM CCl4, 1 hr.  2017.6 1741 161.6 1717.7 
DMSO + 20mM CCl4 + Phen, 1 
hr. 552.2 553.8 161.6 391.4 
DMSO + 20mM CCl4, 2 hr.  2520.6 2534.6 161.6 2366 
DMSO + mM CCl4 + Phen, 2 hr. 39.2 650.6 161.6 183.3 
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Figure 6: PARP Activity Using 6(5H)-Phenanthridinone and Carbon Tetrachloride.  One-
way Paired T-tests were performed between CCl4 and CCl4 + Phen at one and two hours 
of exposure.  Results are expressed as mean ± SEM.  One-tailed Paired T-tests were 
performed with * indicating a significant difference at p<0.05 and with ** indicating a 
significant difference at p<0.01.   
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These PARP activity assay results support the hypothesis that MNNG and CCl4 
increase the numbers of carbon-14 counts of NAD+ that were converted into poly ADP-
ribose, and that 6(5H)-phenanthridinone significantly diminished these increases in 
PARP activity.  The overall carbon-14 count totals were lower in the second experiment 
than in the immediately previous experiment.  This was most likely due in part to the 
lower concentration of cells in the cell culture dishes in this experiment than in the past.   
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Table 5: PARP Activity With MNNG, Carbon Tetrachloride and 6(5H)-
Phenanthridinone.  The co-treatment with 6(5H)-phenanthridinone once again appears to 
reduce the N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) and carbon tetrachloride-
induced increases in PARP activity, as evidenced by diminished carbon-14 counts for the 
insoluble ADP-ribose polymer.  The results are expressed as multiples of the DMSO 
control in Figure 7. 
PARP Activity Assay, HepG2 
Cells     
1.175x10^6 
cells/sample 
MNNG 2 hr. exposure  5 min. count time   
Treatment 
14C CPM 
#1 
14C CPM 
#2 Blank CPM 
Avg. 
Diff. 
0.2% DMSO, 4 hr. 559.2 1123 44 797.1 
0.2% DMSO + 40mM Phen, 4 hr. 541.2 524.4 44 488.8 
200 uM MNNG + 0.2% DMSO 3649 6295.8 44 4928.4 
MNNG + DMSO + 40 mM Phen 1099.4 844.4 44 927.9 
DMSO + 20mM CCl4, 1 hr.  1406.6 1749 44 1533.8 
DMSO + mM CCl4 + Phen, 1 hr. 623.6 335.6 44 435.6 
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Figure 7: PARP Activity With MNNG, Carbon Tetrachloride and 6(5H)-
Phenanthridinone.  One-way Paired T-tests were performed between N-Methyl-N'-Nitro-
N-Nitrosoguanidine (MNNG) and MNNG + Phen, and between CCl4 and CCl4 + Phen at 
one, two and four hours of exposure.  Results are expressed as mean ± SEM.  One-tailed 
Paired T-tests were performed with * indicative of significant difference at p<0.05 and 
with ** indicative of significant difference at p<0.01.   
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In Vitro Conclusions 
In summation, the in vitro experiments strongly suggest that 6(5H)-
phenanthridinone, an inhibitor of PARP, can protect human hepatocytes from the HepG2 
cell line from the free radical-mediated hepatotoxic effects of CCl4.  The results of the 
LDH assays show that there is a relative increase in LDH in the serum when CCl4 is 
incorporated into the culture media and a relative decrease in LDH levels when 6(5H)-
phenanthridinone was also incorporated into the cell culture media.  Similar phenomena 
were observed with the PARP activity assays.  The introduction of CCl4 into the culture 
media resulted in significantly elevated incorporation of NAD+ into the ADP-Ribose 
polymer.  When 6(5H)-phenanthridinone was incorporated in conjunction with CCl4 in 
the culture media, the relative increases in PARP activity were reduced.  These results 
suggest that 6(5H)-phenanthridinone and possibly other specific or non-specific PARP 
inhibitors, could protect the liver from CCl4induced, non glutathione, free radical 
mediated hepatotoxicity. 
 
In Vivo Results 
The fact that carbon tetrachloride induced hepatocellular damage in the in vitro 
assays was strongly suggestive of comparable effects in vivo.  The extent of hepatic 
damage caused by carbon tetrachloride and protection provided by PARP inhibitors was 
determined via serum assays for ALT and AST, TBARS lipid peroxidation assays in liver 
tissue, histopathologic staining, and immunohistochemistry testing of the liver tissue. 
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Serum ALT/AST Assays 
The dose response and time course characteristics of carbon tetrachloride-induced 
hepatotoxicity were determined using serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) assays, which are also constituent tests in human liver 
panels.  The publications which addressed carbon tetrachloride had varied intervals 
between dosage and blood collection, but none of these reported using intervals in excess 
of twenty four (24) hours.  These results strongly suggest that the ALT levels, which are 
indicative of hepatic cell membrane damage, reach their maximum levels at a time period 
of twenty four (24) hours after intraperitoneal administration of carbon tetrachloride.  As 
such, this would be the optimal time to euthanize the male ICR mice for subsequent 
assays. 
 The AST assays were also conducted to determine the optimal time after exposure 
for the determination of damage. As was the case for the ALT assays, the AST levels 
were greatest at a period of twenty four (24) hours after intraperitoneal administration of 
carbon tetrachloride. 
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Table 6: Serum AST Levels at Varied Intervals After Intraperitoneal Carbon 
Tetrachloride Administration.  Results are displayed graphically on the following page. 
AST Time Course  at 600 mg/kg  CCl4         
Treatment Absorbance 
Conc. From 
Curve D.F. Concentration Average Std Dev 
Std 
Error 
Corn Oil 0.232 -6.857 10 -68.571       
Corn Oil 0.276 8.857 10 88.571      
Corn Oil 0.276 8.857 10 88.571      
Corn Oil 0.24 -4.000 10 -40.000      
Corn Oil 0.247 -1.500 10 -15.000      
Corn Oil 0.264 4.571 10 45.714       
Corn Oil 0.276 8.857 10 88.571 26.837 67.219 25.406 
CCl4, 3 hrs. 0.394 51.000 10 510.000       
CCl4, 3 hrs. 0.4 53.143 11 584.571      
CCl4, 3 hrs. 0.372 43.143 10 431.429      
CCl4, 3 hrs. 0.376 44.571 10 445.714      
CCl4, 3 hrs. 0.327 27.071 10 270.714      
CCl4, 3 hrs. 0.319 24.214 10 242.143      
CCl4, 3 hrs. 0.404 54.571 10 545.714      
CCl4, 3 hrs. 0.511 92.786 10 927.857       
CCl4, 3 hrs. 0.41 56.714 10 567.143 502.810 201.107 67.036 
CCl4, 6 hrs. 0.384 47.429 50 2371.429       
CCl4, 6 hrs. 0.558 109.571 11 1205.286      
CCl4, 6 hrs. 0.316 23.143 10 231.429      
CCl4, 6 hrs. 0.456 73.143 10 731.429      
CCl4, 6 hrs. 0.366 41.000 10 410.000      
CCl4, 6 hrs. 0.368 41.714 10 417.143      
CCl4, 6 hrs. 0.323 25.643 10 256.429      
CCl4, 6 hrs. 0.362 39.571 10 395.714       
CCl4, 6 hrs. 0.413 57.786 10 577.857 732.968 682.653 227.551 
CCl4, 18 hrs. 0.321 24.929 10 249.286       
CCl4, 18 hrs. 0.369 42.071 10 420.714      
CCl4, 18 hrs. 0.398 52.429 10 524.286      
CCl4, 18 hrs. 0.35 35.286 10 352.857      
CCl4, 18 hrs. 0.308 20.286 10 202.857      
CCl4, 18 hrs. 0.305 19.214 10 192.143      
CCl4, 18 hrs. 0.322 25.286 10 252.857      
CCl4, 18 hrs. 0.288 13.143 10 131.429       
CCl4, 18 hrs. 0.516 94.571 50 4728.571 783.889 1484.371 494.790 
CCl4, 18 hrs. 0.363 39.929 10 399.286       
CCl4, 24 hrs. 0.348 34.571 11 380.286      
CCl4, 24 hrs. 0.308 20.286 10 202.857      
CCl4, 24 hrs. 0.341 32.071 10 320.714      
CCl4, 24 hrs. 0.555 108.500 10 1085.000      
CCl4, 24 hrs. 0.379 45.643 10 456.429      
CCl4, 24 hrs. 0.585 119.214 50 5960.714      
CCl4, 24 hrs. 0.387 48.500 10 485.000       
CCl4, 24 hrs. 0.326 26.714 10 267.143 1061.937 1854.755 618.252 
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Figure 8: Serum AST Levels at Varied Intervals After Intraperitoneal Carbon 
Tetrachloride Administration.  Adult male ICR mice with an average weight of 30 grams 
were sacrificed at the specified intervals following intraperitoneal administration of 
carbon tetrachloride.  Results are expressed as mean ± SEM.  These results suggest that 
the 24 hour interval is optimal for the collection of blood for serum transaminase assays
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 This AST assay was conducted to determine the optimal time interval following 
intraperitoneal administration of 600 mg/kg CCl4 at which point the AST levels were the 
highest.  This would be the preferred time interval following the injection of CCl4, that 
the mice should be euthanized and the blood should be drawn and centrifuged for the 
serum needed for this assay.  The AST levels were the highest at a period of 24 hours 
following the intraperitoneal administration of this toxicant.  As a result, it was selected 
for subsequent experiments.  The 18-hour interval between intraperitoneal administration 
of CCl4 and euthanasia of the mice resulted in the second-highest serum AST levels.  In 
subsequent serum transaminase assays, the 24 hour interval was used, despite the 
substantial elevation at 18 hours.. 
 Once the optimal interval between carbon tetrachloride administration and 
euthanasia of the mice was established, the dose-response curve was investigated.  The 
concern was that the administered dosage may not be high enough to result in significant 
damage to the hepatocytes.  Also, with the kinetic NADH coupled ultraviolet assay used 
at the time, it was possible to exhaust all the substrate (alanine) before the completion of 
the assay, skewing results downward.  This explained the lower observed ALT level with 
the highest dosage of carbon tetrachloride.  An additional ALT assay was conducted at 
even lower concentrations of carbon tetrachloride.  The results, which are not presented, 
clearly indicated the inadequacy of the kinetic assay method, as the samples one would 
expect to have the highest ALT levels had the lowest levels, likely due to premature 
exhaustion of the substrate.  Although the assay method used changed, the lower toxicant 
level of 0.200 mg/kg carbon tetrachloride was utilized in subsequent experiments, as this 
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level was known to generate ALT levels indicative of substantial hepatocellular damage.
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Table 7: Serum ALT Levels With and Without 0.2 ml/kg Carbon Tetrachloride. 
This experiment used a non-kinetic protocol, which did not allow for substrate 
exhaustion.  The results of this experiment suggest that administration of 0.2 ml/kg of 
carbon tetrachloride caused a significant increase in ALT values.  Elevated ALT levels in 
the serum are indicative of damage to the liver cells, as this assay is a component of the 
liver panel of diagnostic tests.  Results are presented graphically in Figure 9. 
CCl4                
Dosage Sample ID A505 Conc. From Std. D.F. Concentration Average 
Std 
Dev 
Std. 
Error 
  
Reagent 
Blank 0.443             
  
Standard (70 
IU) 0.713             
0.2 ml/kg 1 1.567 291.407 1 291.407       
0.2 ml/kg 2 1.558 289.074 1 289.074       
0.2 ml/kg 3 1.577 294.000 1 294.000       
0.2 ml/kg 4 1.592 297.889 1 297.889       
0.2 ml/kg 5 1.565 290.889 1 290.889       
0.2 ml/kg 6 1.572 292.704 1 292.704       
0.2 ml/kg 7 1.55 287.000 1 287.000       
0.2 ml/kg 8 1.538 283.889 1 283.889 290.856 4.3037 1.5216 
Control 37 0.61 43.296 1 43.296       
Control 38 0.574 33.963 1 33.963 38.630 6.5997 4.6667 
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Figure 9: Serum ALT Levels With and Without 0.2 ml/kg Carbon Tetrachloride.  Serum 
levels of ALT (IU/L) were assayed in mice administered 0.2 ml/kg of CCl4, in 
comparison to control mice given the vehicle, corn oil, alone.  Adult male ICR mice with 
an average weight of 30 grams were sacrificed 24 hours following intraperitoneal 
administration of carbon tetrachloride.  Results are expressed as mean ± SEM.  Two-
sample unequal variance (heteroscedastic) one-way T-tests were performed with ** 
indicating a significant difference at p<0.01.   
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 In this experiment, the first to use a non-kinetic methodology for the ALT assay, 
the results confirmed that the intraperitoneal administration of 0.200 ml/kg of CCl4 could 
produce significant hepatocellular damage.  The absorbance readings at 505 nm for this 
dosage of CCl4 were so high as to extend beyond the linear range of the assay 
methodology.  Unfortunately, there was not enough serum remaining for subsequent 
dilutions of several of the samples.  As a result, the serum ALT concentrations, which 
reflected a statistically significant (p<0.01) increase in serum ALT, if anything, were 
artificially low.  The instructions that came with the assay kit suggested that at higher 
serum concentrations of ALT above the linear range, the absorbance of visible light at 
505 nm did not increase proportionally with serum ALT levels.  All the samples from 
treatment groups involving CCl4 were diluted, with the expectation that the resulting 
absorbances and serum concentrations of ALT would be in the linear range.  This linear 
range includes the standard concentration of ALT, which was provided in conjunction 
with the assay reagents.  As a result, the serum concentrations of ALT derived from the 
comparison with the standard concentration could be multiplied by the applicable dilution 
factors (DF) to produce the final concentrations.  These should prove to be more accurate 
than those in which the undiluted samples yielded absorbance readings beyond the linear 
range of the curve. 
Given the in vitro results, there is reason to believe that inhibition of PARP may 
diminish the hepatotoxic effects associated with CCl4.  The results of serum ALT and 
aspartate aminotransferase (AST) assays when PARP inhibitors were co-treatments with 
carbon tetrachloride confirm these beliefs, with some caveats.  The co-administration of 
 62
6(5H)-phenanthridinone requires dissolution or suspension in dimethyl sulfoxide 
(DMSO), which poses its own health concerns.  Apparently, solubility concerns may 
have precluded the proper dosing with 6(5H)-phenanthridinone, as it was only soluble in 
pure DMSO.  Attempts were made to solubilize 6(5H)-phenanthridinone in corn oil, but 
perhaps due in part to the high viscosity of the corn oil, no amount of heating or mixing 
could result in a solution or stable suspension.  This was evidenced by the white 
precipitate, which began to form beneath the corn oil.  As a result of these solubility 
concerns, it was impossible to ensure that the proper dosage of 6(5H)-phenanthridinone 
was injected into the peritoneal cavity of each of the mice.  This makes water soluble 
PARP inhibitors, such as nicotinamide and aminophylline better choices for 
intraperitoneal administration. 
The other critical reason for selecting aminophylline as a co-treatment is that it 
has been approved by the Food and Drug Administration, albeit for other purposes.  In 
contrast, many other PARP inhibitors have yet to be approved for any purpose.  
Nicotinamide is an essential nutrient, which would likely require less effort for FDA 
approval than most other compounds. 
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Table 8: Serum ALT Levels With Carbon Tetrachloride and Varying 6(5H)-
Phenanthridinone Co-treatments.  The results are presented graphically in Figure 10. 
CCl4 
6(5H)-
phenanthridinone                 
Dosage Treatment Sample  A505 Conc. D.F. Conc. Average Std Dev Std Err. 
    
Reagent 
Blank 0.478             
    Standard 0.726 70 IU/ml           
0.2 ml/kg 0 mg/kg 1 1.628 324.597 5 1622.984       
0.2 ml/kg 0 mg/kg 2 1.629 324.879 5 1624.395       
0.2 ml/kg 0 mg/kg 3 1.568 307.661 5 1538.306       
0.2 ml/kg 0 mg/kg 4 1.62 322.339 5 1611.694       
0.2 ml/kg 0 mg/kg 5 1.639 327.702 5 1638.508       
0.2 ml/kg 0 mg/kg 6 1.621 322.621 5 1613.105       
0.2 ml/kg 0 mg/kg 7 1.6 316.694 5 1583.468 1604.6371 33.7728 12.7649 
0.2 ml/kg 5 mg/kg, Concomitant 8 1.6 316.694 5 1583.468       
0.2 ml/kg 5 mg/kg, Concomitant 9 1.616 321.210 5 1606.048       
0.2 ml/kg 5 mg/kg, Concomitant 10 1.611 319.798 5 1598.992       
0.2 ml/kg 5 mg/kg, Concomitant 11 1.629 324.879 5 1624.395       
0.2 ml/kg 5 mg/kg, Concomitant 12 1.623 323.185 5 1615.927       
0.2 ml/kg 5 mg/kg, Concomitant 13 1.653 331.653 5 1658.266       
0.2 ml/kg 5 mg/kg, Concomitant 14 1.475 281.411 5 1407.056 1584.879 81.8346 30.9306 
0.2 ml/kg 
10 mg/kg, 
Concomitant 15 1.611 319.798 5 1598.992       
0.2 ml/kg 
10 mg/kg, 
Concomitant 16 1.626 324.032 5 1620.161       
0.2 ml/kg 
10 mg/kg, 
Concomitant 17 1.601 316.976 5 1584.879       
0.2 ml/kg 
10 mg/kg, 
Concomitant 18 1.607 318.669 5 1593.347       
0.2 ml/kg 
10 mg/kg, 
Concomitant 19 1.623 323.185 5 1615.927       
0.2 ml/kg 
10 mg/kg, 
Concomitant 20 1.609 319.234 5 1596.169       
0.2 ml/kg 
10 mg/kg, 
Concomitant 21 1.621 322.621 5 1613.105 1603.226 13.2140 4.9944 
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  22 1.623 323.185 5 1615.927       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  23 1.61 319.516 5 1597.581       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  24 1.659 333.347 5 1666.734       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  25 1.6 316.694 5 1583.468       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  26 1.629 324.879 5 1624.395       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  27 1.526 295.806 5 1479.032       
0.2 ml/kg 
5 mg/kg, 3 & 6 hrs. 
Post  28 1.592 314.435 5 1572.177 1591.331 58.3989 22.0727 
0 ml/kg 0 mg/kg 29 1.502 289.032 5 1445.161 red serum omit   
0 ml/kg 0 mg/kg 30 0.477 -0.282 5 -1.411       
0 ml/kg 
10 mg/kg, 
Concomitant 31 0.984 142.823 5 714.113 red serum omit   
0 ml/kg 
10 mg/kg, 
Concomitant 32 0.482 1.129 5 5.645       
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Figure 10: Serum ALT Levels With Carbon Tetrachloride and Varying 6(5H)-
Phenanthridinone Co-treatments.  Adult male ICR mice with an average weight of 30 
grams were sacrificed 24 hours following intraperitoneal administration of carbon 
tetrachloride.  Results are expressed as mean ± SEM.  Two-sample unequal variance 
(heteroscedastic) one-way T-tests were performed.  There were no significant reductions 
in the serum ALT levels as a result of the different co-treatment intervals for 6(5H)-
phenanthridinone. 
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 The results of this experiment were disconcerting, because 6(5H)-
phenanthridinone appeared to be extremely effective against the hepatotoxic effects of 
CCl4 in the in vitro studies.  The results of these in vitro studies strongly suggested that 
the addition of 6(5H)-phenanthridinone to the cell culture media substantially, and in 
most cases, significantly reduced the hepatotoxic effects of CCl4, as evidenced by the 
reduction in LDH levels in the culture media, and diminished PARP activity.  The 
primary issue preventing the use of 6(5H)-phenanthridinone appears to be that of 
solubility.  I was incapable of solubilizing 6(5H)-phenanthridinone in corn oil or saline.  
It would have been possible to solubilize 6(5H)-phenanthridinone in pure DMSO.  
However, Banasik and Ueda (1994) also reported that DMSO is a PARP inhibitor in its 
own right.  Also, because of potential health concerns, specifically related to hepatic 
damage, DMSO may not make for the safest vehicle for otherwise insoluble drugs.  
Fortunately, Pacher et al (2002) have discovered water soluble phenanthridinone 
derivatives.  In the following experiment, I again tried administering 6(5H)-
phenanthridinone, only this time via multiple intraperitoneal injections at different 
intervals following the intraperitoneal administration of CCl4 , with the hopes of finding 
it effective at one or more of these time points. 
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Table 9: Serum ALT Levels with Carbon Tetrachloride and Varied Numbers of 6(5H)-
Phenanthridinone Treatments.  These results are displayed graphically in Figure 11. 
 
CCl4 Phen                
Dosage Treatment Sample A505 Conc. D.F. Concentration Avg. Std Dev Std Err 
    Reagent Bl. 0.467             
    Standard 0.702 70 IU/l           
0.1 
ml/kg 0 mg/kg 1 1.63 346.426 5 1732.128       
0.1 
ml/kg 0 mg/kg 2 1.53 316.638 5 1583.191       
0.1 
ml/kg 0 mg/kg 3 1.506 309.489 5 1547.447       
0.1 
ml/kg 0 mg/kg 4 1.613 341.362 5 1706.809       
0.1 
ml/kg 0 mg/kg 5 1.663 356.255 5 1781.277 1670.1702 100.1899 44.8063 
0.1 
ml/kg 10 mg/kg, 45 min post 6 1.633 347.319 5 1736.596       
0.1 
ml/kg 10 mg/kg, 45 min post 7 1.625 344.936 5 1724.681       
0.1 
ml/kg 10 mg/kg, 45 min post 8 1.651 352.681 5 1763.404       
0.1 
ml/kg 10 mg/kg, 45 min post 9 1.645 350.894 5 1754.468       
0.1 
ml/kg 10 mg/kg, 45 min post 10 1.587 333.617 5 1668.085 1729.447 37.4775 16.7604 
0.1 
ml/kg 10 mg/kg, 45 & 90 min 11 1.596 336.298 5 1681.489       
0.1 
ml/kg 10 mg/kg, 45 & 90 min 12 1.641 349.702 5 1748.511       
0.1 
ml/kg 10 mg/kg, 45 & 90 min 13 1.389 274.638 5 1373.191       
0.1 
ml/kg 10 mg/kg, 45 & 90 min 14 1.527 315.745 5 1578.723       
0.1 
ml/kg 10 mg/kg, 45 & 90 min 15 1.3 248.128 5 1240.638 1524.511 212.8605 95.1941 
0.1 
ml/kg 
10 mg/kg, 45, 90 & 135 
min 16 1.574 329.745 5 1648.723       
0.1 
ml/kg 
10 mg/kg, 45, 90 & 135 
min 17 1.647 351.489 5 1757.447       
0.1 
ml/kg 
10 mg/kg, 45, 90 & 135 
min 18 1.195 216.851 5 1084.255       
0.1 
ml/kg 
10 mg/kg, 45, 90 & 135 
min 19 1.596 336.298 5 1681.489       
0.1 
ml/kg 
10 mg/kg, 45, 90 & 135 
min 20 1.589 334.213 5 1671.064 1568.596 273.8227 122.4572 
0.1 
ml/kg 
10 mg/kg, 45, 90, 135, 
180 21 1.639 349.106 5 1745.532       
0.1 
ml/kg 
10 mg/kg, 45, 90, 135, 
180 22 1.625 344.936 5 1724.681       
0.1 
ml/kg 
10 mg/kg, 45, 90, 135, 
180 23 1.645 350.894 5 1754.468       
0.1 
ml/kg 
10 mg/kg, 45, 90, 135, 
180 24 1.548 322.000 5 1610.000       
0.1 
ml/kg 
10 mg/kg, 45, 90, 135, 
180 25 1.04 170.681 5 853.404 1537.617 386.8566 173.0076 
0 ml/kg 
10 mg/kg, 45, 90, 135, 
180 26 0.882 123.617 5 618.085       
0 ml/kg 
10 mg/kg, 45, 90, 135, 
180 27 0.475 2.383 5 11.915       
0 ml/kg 
10 mg/kg, 45, 90, 135, 
180 28 0.501 10.128 5 50.638       
0 ml/kg 
10 mg/kg, 45, 90, 135, 
180 29 0.5 9.830 5 49.149 182.447 290.9775 145.4887 
0 ml/kg 0 mg/kg 30 0.491 7.149 5 35.745       
0 ml/kg 0 mg/kg 31 0.576 32.468 5 162.340 red serum     
0 ml/kg 0 mg/kg 32 0.495 8.340 5 41.702 79.929 71.4325 41.2415 
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Figure 11: Serum ALT Levels with Carbon Tetrachloride and Varied Numbers of 6(5H)-
Phenanthridinone Treatments.  Adult male ICR mice with an average weight of 30 grams 
were sacrificed 24 hours following intraperitoneal administration of carbon tetrachloride.  
Results are expressed as mean ± SEM.  Two-sample unequal variance (heteroscedastic) 
one-way T-tests were performed.  There were no significant reductions in the serum ALT 
levels as a result of the different numbers of co-treatments with 6(5H)-phenanthridinone.   
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 The results of this experiment strongly suggest that there still appears to be a 
solubility problem, because the thorough vortex mixing of 6(5H)-phenanthridinone in 
saline merely produced a suspension.  The particles of 6(5H)-phenanthridinone that were 
suspended in saline may not have been effectively delivered through the 25 gauge needle 
into the peritoneal cavity. 
 The next factor to test was whether, by administering the 6(5H)-phenanthridinone 
to the mice at a later period following carbon tetrachloride exposure, more of the 6(5H)-
phenanthridinone may be available to prevent hepatocellular damage.  This experiment 
failed to yield any results indicative of a protective effect by 6(5H)-phenanthridinone 
against carbon tetrachloride-induced hepatotoxicity.  This suggests that delaying the 
administration of 6(5H)-phenanthridinone does not protect the livers from carbon 
tetrachloride-induced hepatocellular damage. 
In the following experiment, I again tried administering 6(5H)-phenanthridinone, 
only at different intervals following the intraperitoneal administration of CCl4 , with the 
hopes of finding it effective at one of these time points. 
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Table 10: Serum ALT Levels With Delayed 6(5H)-Phenanthridinone Administration.  
The results are displayed in graphical form in Figure 12. 
CCl4 Phen                 
Dosage Treatment Sample  A505 Conc. D.F. Conc. Avg Std Dev Std Err 
    
Reagent 
Blank 0.488             
    Standard 0.721 
70 
IU/ml           
0 ml/kg 0 mg/kg 1 0.512 7.210 5 36.052       
0 ml/kg 0 mg/kg 2 0.458 -9.013 5 -45.064       
0 ml/kg 0 mg/kg 3 0.588 30.043 5 150.215 47.0672 98.1044 56.6406 
0 ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 4 0.476 -3.605 5 -18.026       
0 ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 5 0.494 1.803 5 9.013       
0 ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 6 0.559 21.330 5 106.652       
0 ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 7 0.589 30.343 5 151.717 62.3391 80.1129 40.0564 
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 8 1.667 354.206 5 1771.030       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 9 1.661 352.403 5 1762.017       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 10 1.656 350.901 5 1754.506       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 11 1.648 348.498 5 1742.489       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 12 1.655 350.601 5 1753.004       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 13 1.501 304.335 5 1521.674       
0.1 
ml/kg 
10 mg/kg, 3 & 6 hrs. 
post 15 1.512 307.639 5 1538.197 1691.845 111.0495 41.9728 
0.1 
ml/kg 10 mg/kg, 3 hrs. post 16 1.566 323.863 5 1619.313       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 17 1.622 340.687 5 1703.433       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 18 1.619 339.785 5 1698.927       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 19 1.64 346.094 5 1730.472       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 20 1.65 349.099 5 1745.494       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 21 1.601 334.378 5 1671.888       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 22 1.646 347.897 5 1739.485       
0.1 
ml/kg 10 mg/kg, 3 hrs. post 23 1.634 344.292 5 1721.459 1703.809 41.7736 14.7692 
0.1 
ml/kg 0 mg/kg 24 1.666 353.906 5 1769.528       
0.1 
ml/kg 0 mg/kg 25 1.646 347.897 5 1739.485       
0.1 
ml/kg 0 mg/kg 26 1.627 342.189 5 1710.944       
0.1 
ml/kg 0 mg/kg 27 1.639 345.794 5 1728.970       
0.1 
ml/kg 0 mg/kg 28 1.636 344.893 5 1724.464       
0.1 
ml/kg 0 mg/kg 29 1.627 342.189 5 1710.944       
0.1 
ml/kg 0 mg/kg 30 1.629 342.790 5 1713.948       
0.1 
ml/kg 0 mg/kg 31 1.634 344.292 5 1721.459 1727.468 19.6020 6.9304 
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Figure 12: Serum ALT Levels With Delayed 6(5H)-Phenanthridinone Administration.  
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  The delayed 
administration of 6(5H)-phenanthridinone did not significantly reduce the CCl4-induced 
elevation in serum ALT levels.  Results are expressed as mean ± SEM.  Two-sample 
unequal variance (heteroscedastic) one-way T-tests were performed.  There were no 
significant reductions in the serum ALT levels as a result of the different numbers of 
delayed co-treatments with 6(5H)-phenanthridinone.
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 The results of this experiment strongly suggested that, shy of using high 
percentages of DMSO, in which 6(5H)-phenanthridinone is soluble, there was no feasible 
means of delivering 6(5H)-phenanthridinone effectively via intraperitoneal injection.  As 
a result, I decided to try other PARP inhibitors that, despite their substantially greater 
effective concentrations, may be more effective against the hepatotoxic effects of CCl4, 
when administered via intraperitoneal injection. 
 Following these experiments with 6(5H)-phenanthridinone and 4-
aminobenzamide, it became critical to determine whether any PARP inhibitors could be 
proven effective at reducing the hepatotoxic effects of carbon tetrachloride.  
Nicotinamide (a.k.a. niacinamide) has been reportedly shown (Gibb and Brody, 1967) to 
reduce the hepatotoxic effects of carbon tetrachloride, suggesting it would be a good co-
treatment to test in the ICR mice.  The following results confirm the fact that 
nicotinamide, for reasons that may be related or unrelated to the inhibition of PARP-1, 
was capable of reducing ALT levels.  Much higher dosages (250 and 500 mg/kg) of 
nicotinamide were used in the following experiments, due to its higher in vitro PARP-1 
inhibition concentration (Banasik, 1994).  These results suggest that when sufficiently 
high levels of nicotinamide are used, it may effectively protect the livers against the 
hepatotoxic effects of carbon tetrachloride.
 72
 
Table 11: Serum ALT Levels With Nicotinamide and Carbon Tetrachloride.  Results are 
displayed in graphical format on Figure 13. 
CCl4 Nicotinamide               
Dosage Dosage A505 Conc. D.F. Conc. Avg Std Dev Std Err 
  Rgnt. Blank 0.452             
  Standard 0.71 
70 
IU/ml           
0 ml/kg 0 mg/kg 0.465 3.527 5 17.636       
0 ml/kg 0 mg/kg 0.469 4.612 5 23.062       
0 ml/kg 0 mg/kg 0.477 6.783 5 33.915 24.8708 8.2889 4.7856 
0.025 
ml/kg 0 mg/kg 1.38 251.783 5 1258.915       
0.025 
ml/kg 0 mg/kg 1.379 251.512 5 1257.558       
0.025 
ml/kg 0 mg/kg 1.227 210.271 5 1051.357 1189.2765 119.4441 68.9611 
0 ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.468 4.341 5 21.705       
0 ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.481 7.868 5 39.341       
0 ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.459 1.899 5 9.496 23.514 15.0045 8.6628 
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.464 3.256 5 16.279       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.864 111.783 5 558.915       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.747 80.039 5 400.194       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 1.052 162.791 5 813.953       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.933 130.504 5 652.519       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 1.136 185.581 5 927.907       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.912 124.806 5 624.031       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.787 90.891 5 454.457       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.516 17.364 5 86.822       
0.025 
ml/kg 
250 mg/kg, 1 hr. post 
CCl4 0.961 138.101 5 690.504 522.558 292.8270 92.6000 
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Figure 13: Serum ALT Levels With Nicotinamide and Carbon Tetrachloride. 
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  Results are expressed as 
mean ± SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were 
performed, with ** indicative of a significant difference at p<0.01.  Nicotinamide appears 
to provide some measure of protection against CCl4-induced increases in serum ALT 
levels, at these lower dosages of carbon tetrachloride, when administered via 
intraperitoneal injection one hour following the toxicant.   
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 The results of this experiment showed some promise, as the intraperitoneal 
administration of 250 mg/kg of nicotinamide one hour following the intraperitoneal 
injection of CCl4 was capable of reducing the adverse effects of this hepatotoxicant.  
 Although the hepatoprotective effect of 250 mg/kg nicotinamide against 0.025 
ml/kg CCl4 was significant, there was still a substantial elevation in ALT levels over 
those for the controls, which is still likely indicative of substantial hepatocellular damage.  
The next experiment tested whether a higher dosage (500 mg/kg) of nicotinamide would 
be more hepatoprotective against CCl4, further reducing serum ALT levels closer to those 
of the control mice. 
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Table 12: Serum ALT Levels at Two Different Dosages of Nicotinamide.  Results are 
displayed graphically in Figure 14. 
 
  ALT                   
Treatment A505 Blank Diff. Std Diff/St-bl DF Conc Avg Std Dev Std Err 
Control 0.529 0.412 0.117 0.650 0.4916 1 34.412       
Control 0.514 0.412 0.102 0.650 0.4286 1 30.000       
Control 0.539 0.412 0.127 0.650 0.5336 1 37.353       
Control 0.514 0.412 0.102 0.650 0.4286 1 30.000       
Control 0.62 0.412 0.208 0.650 0.8739 1 61.176       
Control 0.55 0.412 0.138 0.650 0.5798 1 40.588       
Control 0.563 0.412 0.151 0.650 0.6345 1 44.412       
Control 0.541 0.412 0.129 0.650 0.5420 1 37.941 39.4853 10.0613 3.5572 
Nic 250 Control 0.571 0.424 0.147 0.669 0.6000 1 42.000       
Nic 250 Control 0.631 0.424 0.207 0.669 0.8449 1 59.143       
Nic 250 Control 0.592 0.424 0.168 0.669 0.6857 1 48.000       
Nic 250 Control 0.527 0.424 0.103 0.669 0.4204 1 29.429       
Nic 250 Control 0.612 0.424 0.188 0.669 0.7673 1 53.714       
Nic 250 Control 0.389 0.412 
-
0.023 0.650 -0.0966 1 -6.765       
Nic 250 Control 0.507 0.412 0.095 0.650 0.3992 1 27.941       
Nic 250 Control 0.555 0.412 0.143 0.650 0.6008 1 42.059       
Nic 250 Control 0.593 0.412 0.181 0.650 0.7605 1 53.235 38.7507 20.0998 6.6999 
Nic 500 Control 0.509 0.412 0.097 0.650 0.4076 1 28.529       
Nic 500 Control 0.51 0.412 0.098 0.650 0.4118 1 28.824       
Nic 500 Control 0.512 0.412 0.100 0.650 0.4202 1 29.412       
Nic 500 Control 0.589 0.412 0.177 0.650 0.7437 1 52.059       
Nic 500 Control 0.488 0.412 0.076 0.650 0.3193 1 22.353       
Nic 500 Control 0.58 0.412 0.168 0.650 0.7059 1 49.412       
Nic 500 Control 0.569 0.412 0.157 0.650 0.6597 1 46.176       
Nic 500 Control 0.658 0.412 0.246 0.650 1.0336 1 72.353       
Nic 500 Control 0.52 0.412 0.108 0.650 0.4538 1 31.765 40.0980 16.0725 5.3575 
0.025 ml/kg CCl4 1.178 0.424 0.754 0.669 3.0776 5 1077.143       
0.025 ml/kg CCl4 1.513 0.424 1.089 0.669 4.4449 5 1555.714       
0.025 ml/kg CCl4 1.603 0.424 1.179 0.669 4.8122 5 1684.286       
0.025 ml/kg CCl4 1.603 0.424 1.179 0.669 4.8122 5 1684.286       
0.025 ml/kg CCl4 1.196 0.424 0.772 0.669 3.1510 5 1102.857       
0.025 ml/kg CCl4 1.346 0.424 0.922 0.669 3.7633 5 1317.143       
0.025 ml/kg CCl4 1.612 0.424 1.188 0.669 4.8490 5 1697.143       
0.025 ml/kg CCl4 1.389 0.424 0.965 0.669 3.9388 5 1378.571       
0.025 ml/kg CCl4 1.356 0.424 0.932 0.669 3.8041 5 1331.429 1425.4 243.1383 81.0461 
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Table 12 (Continued) 
CCl4/Nic 250 1.244 0.424 0.820 0.669 3.3469 5 1171.429       
CCl4/Nic 250 1.112 0.424 0.688 0.669 2.8082 5 982.857       
CCl4/Nic 250 0.579 0.424 0.155 0.669 0.6327 5 221.429       
CCl4/Nic 250 0.402 0.424 
-
0.022 0.669 
-
0.0898 5 -31.429       
CCl4/Nic 250 1.213 0.424 0.789 0.669 3.2204 5 1127.143       
CCl4/Nic 250 1.052 0.424 0.628 0.669 2.5633 5 897.143       
CCl4/Nic 250 0.548 0.424 0.124 0.669 0.5061 5 177.143       
CCl4/Nic 250 0.556 0.424 0.132 0.669 0.5388 5 188.571       
CCl4/Nic 250 0.778 0.424 0.354 0.669 1.4449 5 505.714       
CCl4/Nic 250 0.883 0.424 0.459 0.669 1.8735 5 655.714       
CCl4/Nic 250 0.554 0.424 0.130 0.669 0.5306 5 185.714       
CCl4/Nic 250 1.402 0.424 0.978 0.669 3.9918 5 1397.143       
CCl4/Nic 250 0.458 0.424 0.034 0.669 0.1388 5 48.571       
CCl4/Nic 250 0.881 0.424 0.457 0.669 1.8653 5 652.857       
CCl4/Nic 250 1.389 0.424 0.965 0.669 3.9388 5 1378.571 637.24 495.7453 128.0009 
CCl4/Nic 500 0.474 0.424 0.050 0.669 0.2041 5 71.429       
CCl4/Nic 500 0.486 0.424 0.062 0.669 0.2531 5 88.571       
CCl4/Nic 500 0.569 0.424 0.145 0.669 0.5918 5 207.143       
CCl4/Nic 500 0.829 0.424 0.405 0.669 1.6531 5 578.571       
CCl4/Nic 500 0.627 0.424 0.203 0.669 0.8286 5 290.000       
CCl4/Nic 500 0.803 0.424 0.379 0.669 1.5469 5 541.429       
CCl4/Nic 500 0.772 0.424 0.348 0.669 1.4204 5 497.143       
CCl4/Nic 500 0.829 0.424 0.405 0.669 1.6531 5 578.571       
CCl4/Nic 500 0.435 0.424 0.011 0.669 0.0449 5 15.714       
CCl4/Nic 500 0.413 0.424 
-
0.011 0.669 
-
0.0449 5 -15.714       
CCl4/Nic 500 0.437 0.424 0.013 0.669 0.0531 5 18.571       
CCl4/Nic 500 0.883 0.424 0.459 0.669 1.8735 5 655.714       
CCl4/Nic 500 0.39 0.424 
-
0.034 0.669 
-
0.1388 5 -48.571       
CCl4/Nic 500 0.681 0.424 0.257 0.669 1.0490 5 367.143       
CCl4/Nic 500 1.075 0.424 0.651 0.669 2.6571 5 930.000 318.3810 300.2496 77.5241 
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Figure 14: Serum ALT Levels at Two Different Dosages of Nicotinamide.  Adult male 
ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Results are expressed as mean ± 
SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were performed, 
with ** indicating a significant difference at p<0.01.  Nicotinamide was found to 
significantly reduce the CCl4-induced increases in serum ALT levels in a dose-dependent 
fashion.  This suggests that nicotinamide protects against the hepatotoxic effects of CCl4 
in a dose-dependent fashion.  
 78
 The results of this experiment confirmed the expectation that the hepatoprotective 
effects of nicotinamide were dose-dependent in nature.  Although both the 250 and 500 
mg/kg dosages of nicotinamide produced statistically significant (p < 0.01) reductions in 
serum ALT levels, the higher dosage was able to approach the levels of the control mice.  
The 250 and 500 mg/kg nicotinamide co-treatments reduced the CCl4induced serum 
ALT elevations by 55% and 78%, respectively. 
Since the purpose of this line of research was to determine if as a class of drugs, 
PARP inhibitors, could potentially protect against CCl4induced free radical mediated 
hepatotoxicity, it would be best to determine whether additional PARP inhibitors could 
mitigate this hepatic damage.  The use of another PARP inhibitor may also help 
indirectly determine if the hepatoprotective effects of nicotinamide were merely a 
function of nicotinamide being a component of NAD+, the substrate for PARP.  The 
following experiment compared the efficacies of nicotinamide and aminophylline for 
protection of hepatocytes against carbon tetrachloride-induced toxic effects.  Although 
both co-treatments offered some measure of protection against carbon tetrachloride-
induced hepatotoxicity, aminophylline appeared to be more effective than nicotinamide. 
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Table 13: Serum ALT Levels Using Carbon Tetrachloride, Aminophylline and 
Nicotinamide.  Results of this experiment are displayed graphically in Figure 15. 
Treatment A505 Blank 
Samp-
Bl 
Std-
bl 
R/(st-
bl) *70 
D 
F Conc Avg. Std.Dev Std.Err 
control 0.533 0.46 0.073 0.174 0.420 29.368 1 29.368       
control 0.531 0.46 0.071 0.174 0.408 28.563 1 28.563       
control 0.594 0.46 0.134 0.174 0.770 53.908 1 53.908       
control 0.519 0.46 0.059 0.174 0.339 23.736 1 23.736 33.894 13.573 6.786 
50 mg/kg amino 0.621 0.46 0.161 0.174 0.925 64.770 1 64.770       
50 mg/kg amino 0.531 0.46 0.071 0.174 0.408 28.563 1 28.563       
50 mg/kg amino 0.51 0.46 0.05 0.174 0.287 20.115 1 20.115       
50 mg/kg amino 0.477 0.46 0.017 0.174 0.098 6.839 1 6.839 30.072 24.800 12.400 
500 mg/kg nic 0.62 0.46 0.16 0.174 0.920 64.368 1 64.368       
500 mg/kg nic 0.585 0.46 0.125 0.174 0.718 50.287 1 50.287       
500 mg/kg nic 0.605 0.46 0.145 0.174 0.833 58.333 1 58.333       
500 mg/kg nic 0.622 0.46 0.162 0.174 0.931 65.172 1 65.172       
500 mg/kg nic 0.611 0.46 0.151 0.174 0.868 60.747 1 60.747 59.782 5.985 2.676 
ccl4/amino 0.803 0.46 0.343 0.174 1.971 137.989 5 689.943       
ccl4/amino 0.626 0.46 0.166 0.174 0.954 66.782 5 333.908       
ccl4/amino 0.783 0.46 0.323 0.174 1.856 129.943 5 649.713       
ccl4/amino 0.765 0.46 0.305 0.174 1.753 122.701 5 613.506       
ccl4/amino 0.737 0.46 0.277 0.174 1.592 111.437 5 557.184 568.851 140.116 62.662 
ccl4/nic 0.693 0.46 0.233 0.174 1.339 93.736 5 468.678       
ccl4/nic 0.75 0.46 0.29 0.174 1.667 116.667 5 583.333       
ccl4/nic 0.791 0.46 0.331 0.174 1.902 133.161 5 665.805       
ccl4/nic 0.923 0.46 0.463 0.174 2.661 186.264 5 931.322 662.284 196.732 87.981 
0.025 ml/kg CCl4 1.081 0.46 0.621 0.174 3.569 249.828 5 1249.138       
0.025 ml/kg CCl4 0.92 0.46 0.46 0.174 2.644 185.057 5 925.287       
0.025 ml/kg CCl4 1.175 0.46 0.715 0.174 4.109 287.644 5 1438.218       
0.025 ml/kg CCl4 1.098 0.46 0.638 0.174 3.667 256.667 5 1283.333       
0.025 ml/kg CCl4 1.068 0.46 0.608 0.174 3.494 244.598 5 1222.989 1223.793 186.596 83.448 
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Figure 15: Serum ALT Levels Using Carbon Tetrachloride, Aminophylline and 
Nicotinamide.  Adult male ICR mice with an average weight of 30 grams were sacrificed 
24 hours following intraperitoneal administration of carbon tetrachloride.  Results are 
expressed as mean ± SEM.  Two-sample unequal variance (heteroscedastic) one-way T-
tests were performed, with ** indicating a significant difference at p<0.01.   
These results suggest that both aminophylline and nicotinamide are capable of protecting 
the liver cells from CCl4-induced hepatocellular damage. 
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 The results of this experiment showed that both non-specific PARP inhibitors 
significantly (p < 0.01) reduced the CCl4-induced increases in serum ALT, although 
neither co-treatment resulted in ALT levels comparable to those of the control groups.  
The reductions in serum ALT concentrations as a result of the nicotinamide (500 mg/kg) 
and aminophylline (50 mg/kg) were 46% and 54%, respectively. 
 The next experiment varied the dosages of the co-treatment, aminophylline, with 
the goal of determining what could be the optimal dosage, reducing the CCl4induced 
increase in serum ALT the most, without causing any adverse effects.  The highest of 
these dosages of aminophylline most likely produced serum theophylline levels in excess 
of the normal therapeutic concentrations, so the mice had to be observed closely to 
determine if they were showing any signs of theophylline overdose.  
 
 The question arose whether aminophylline reduced the hepatotoxic effects of 
carbon tetrachloride, or simply delayed them.  This question was answered by conducting 
a seventy-two (72) hour study for mice treated with carbon tetrachloride and 
aminophylline, with mice euthanized in twelve (12) hour intervals beyond 24 hours for 
collection of blood for the serum assays.  There does not appear to be a significant 
delayed toxic effect when aminophylline is administered as a co-treatment.  Therefore, 
aminophylline appears to be protective against carbon tetrachloride, and not just a 
mechanism to delay the onset of hepatotoxic effects.
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Table 14: 72-Hour Serum ALT Levels With Aminophylline and Carbon Tetrachloride. 
Results of this experiment are provided in bar graph format on the following page. 
Treatment A505 Blank 
Samp-
Bl 
Std-
bl R/(st-bl) *70 
D 
F Conc Avg. Std.Dev Std.Err 
36 hr CCl4 0.514 0.47 0.044 0.256 0.172 12.031 5 60.156       
36 hr CCl4 0.611 0.47 0.141 0.256 0.551 38.555 5 192.773       
36 hr CCl4 0.651 0.47 0.181 0.256 0.707 49.492 5 247.461       
36 hr CCl4 0.546 0.47 0.076 0.256 0.297 20.781 5 103.906 151.07 84.696 42.348 
36-hr 
CCl4/amino 0.465 0.47 -0.005 0.256 -0.02 -1.367 5 -6.836       
36-hr 
CCl4/amino 0.509 0.47 0.039 0.256 0.152 10.664 5 53.32       
36-hr 
CCl4/amino 0.464 0.47 -0.006 0.256 -0.023 -1.641 5 -8.203       
36-hr 
CCl4/amino 0.484 0.47 0.014 0.256 0.055 3.828 5 19.141 14.355 28.862 14.431 
48-hr 
CCl4/amino 0.53 0.47 0.06 0.256 0.234 16.406 5 82.031       
48-hr 
CCl4/amino 0.461 0.47 -0.009 0.256 -0.035 -2.461 5 -12.305       
48-hr 
CCl4/amino 0.469 0.47 -0.001 0.256 -0.004 -0.273 5 -1.367       
48-hr 
CCl4/amino 0.483 0.47 0.013 0.256 0.051 3.555 5 17.773 21.533 42.204 21.102 
60-hr 
CCl4/amino 0.486 0.47 0.016 0.256 0.063 4.375 5 21.875       
60-hr 
CCl4/amino 0.5 0.47 0.03 0.256 0.117 8.203 5 41.016       
60-hr 
CCl4/amino 0.495 0.47 0.025 0.256 0.098 6.836 5 34.18       
60-hr 
CCl4/amino 0.506 0.47 0.036 0.256 0.141 9.844 5 49.219 36.572 11.567 5.784 
72-hr 
CCl4/amino 0.495 0.47 0.025 0.256 0.098 6.836 5 34.18       
72-hr 
CCl4/amino 0.489 0.47 0.019 0.256 0.074 5.195 5 25.977       
72-hr 
CCl4/amino 0.443 0.47 -0.027 0.256 -0.105 -7.383 5 -36.914       
72-hr 
CCl4/amino 0.477 0.47 0.007 0.256 0.027 1.914 5 9.57 8.203 31.771 15.885 
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Figure 16: 72-Hour Serum ALT Levels With Aminophylline and Carbon Tetrachloride.  
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  Results are expressed as 
mean ± SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were 
performed, with * indicative of significant difference at p<0.05.  This time course 
experiment was performed to determine whether intraperitoneal administration of 
aminophylline (50 mg/kg) one hour following the CCl4 (0.025 ml/kg) injection, was 
capable of reducing the CCl4-induced increase in serum ALT levels, or whether it merely 
delayed the metabolism of CCl4, and the resulting peak serum ALT concentration.  
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 This experiment confirmed what was expected, that aminophylline actually 
reduced the hepatotoxicity of CCl4, as evidenced by diminished serum ALT levels, rather 
than merely postponing the adverse effect.  Had the hepatotoxic effects of CCl4 been 
merely delayed, there would have been an increase in serum ALT levels at some point 
after 24 hours.  One may assume that, since the relative reduction in serum ALT levels 
was less at 12 hours than was observed at 24 hours in previous studies, that there may be 
a lag period of more than 12 hours before aminophylline begins to provide substantial 
hepatoprotection against CCl4. 
 The next step in this series of experiments with aminophylline was to determine 
whether higher levels of this co-treatment, administered three times, at thirty (30), sixty 
(60) and one hundred twenty (120) minutes following the carbon tetrachloride were more 
beneficial or were potentially harmful to the mice.  The use of multiple injections allowed 
for the gradual increase of aminophylline, and ultimately theophylline, in the blood 
stream and tissues.  Unfortunately, mice administered 0.025 ml/kg carbon tetrachloride 
and either 100 or 200 mg/kg aminophylline three times did not survive, eliminating those 
higher co-treatments from further study.  As a result, future studies focused on the results 
of administering 50 mg/kg of aminophylline at various intervals following the injection 
of CCl4. 
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Table 15: Serum ALT Levels With Three Administrations of Aminophylline.  The results 
of this experiment are provided in a graph in Figure 17. 
Treatment A505 Blank A-Bl Std-Bl (R)/Cal DF Conc Avg Std Dev Std Err 
Control 0.374 0.367 0.007 0.289 0.0242 1 1.696       
Control 0.393 0.367 0.026 0.289 0.0900 1 6.298       
Control 0.375 0.367 0.008 0.289 0.0277 1 1.938       
Control 0.439 0.367 0.072 0.289 0.2491 1 17.439 6.8426 7.3743 3.6871 
50 Animophylline 
x3 0.479 0.367 0.112 0.289 0.3875 1 27.128       
50 Animophylline 
x3 0.388 0.367 0.021 0.289 0.0727 1 5.087       
50 Animophylline 
x3 0.431 0.367 0.064 0.289 0.2215 1 15.502       
50 Animophylline 
x3 0.437 0.367 0.07 0.289 0.2422 1 16.955 16.1678 9.0182 4.5091 
0.025 ml/kg CCl4 0.874 0.367 0.507 0.289 1.7543 5 614.014       
0.025 ml/kg CCl4 0.872 0.367 0.505 0.289 1.7474 5 611.592       
0.025 ml/kg CCl4 0.63 0.367 0.263 0.289 0.9100 5 318.512       
0.025 ml/kg CCl4 0.899 0.367 0.532 0.289 1.8408 5 644.291       
0.025 ml/kg CCl4 0.581 0.367 0.214 0.289 0.7405 5 259.170       
0.025 ml/kg CCl4 0.535 0.367 0.168 0.289 0.5813 5 203.460       
0.025 ml/kg CCl4 1.012 0.367 0.645 0.289 2.2318 5 781.142       
0.025 ml/kg CCl4 0.954 0.367 0.587 0.289 2.0311 5 710.900 517.8849 222.3591 78.6158 
50 Amino + CCl4 0.449 0.367 0.082 0.289 0.2837 5 99.308       
50 Amino + CCl4 0.461 0.367 0.094 0.289 0.3253 5 113.841       
50 Amino + CCl4 0.382 0.367 0.015 0.289 0.0519 5 18.166       
50 Amino + CCl4 0.453 0.367 0.086 0.289 0.2976 5 104.152       
50 Amino + CCl4 0.586 0.367 0.219 0.289 0.7578 5 265.225       
50 Amino + CCl4 0.376 0.367 0.009 0.289 0.0311 5 10.900       
50 Amino + CCl4 0.506 0.367 0.139 0.289 0.4810 5 168.339       
50 Amino + CCl4 0.388 0.367 0.021 0.289 0.0727 5 25.433 100.6704 86.4962 30.5810 
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Figure 17: Serum ALT Levels With Three Administrations of Aminophylline.  Adult 
male ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Results are expressed as mean ± 
SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were performed, 
with ** indicating a significant difference at p<0.01.  The three administrations of 50 
mg/kg aminophylline via intraperitoneal injection at 30, 60 and 120 minutes following a 
single intraperitoneal dosage of CCl4 (0.025 ml/kg) reduced the CCl4-induced increases 
in ALT levels over eighty percent.
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 The serum ALT assay results for this experiment strongly suggest that the thrice 
administration of aminophylline (50 mg/kg) at 30, 60 and 120 minutes following the 
intraperitoneal administration of 0.025 ml/kg CCl4 protects against the hepatotoxic ffects 
of CCl4.  The 81% reduction in serum ALT levels as a result of the co-treatment with 
aminophylline was statistically significant (p < 0.01).  There was, however, a concern 
that one of the mice given both CCl4 and aminophylline exhibited a potential sign of 
theophylline toxicity (twitching) as a result of the three dosages of aminophylline, 
perhaps exacerbated in some fashion by the prior administration of CCl4. 
 In response to the prior results, the next experiment further addressed potential 
concerns about aminophylline by opting for only two intraperitoneal administrations of 
50 mg/kg aminophylline, at 30 and 60 minutes following the carbon tetrachloride, in lieu 
of three dosages.  Although there was a significant hepatoprotective effect, the positive 
effects were substantially lower than when aminophylline was administered three times. 
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Table 16: Serum ALT Levels With Two Administrations of Aminophylline.  The results 
of this experiment are provided in a bar chart in Figure 18. 
 
  CCl4+Amino   ALT                  
No Treatment A505 Blank A505-Bl 
Std-
Bl (R)/Cal DF Conc. Avg Std Dev Std Err 
25 Control 0.359 0.302 0.057 0.344 0.1657 1 11.599       
26 Control 0.314 0.302 0.012 0.344 0.0349 1 2.442       
27 Control 0.412 0.302 0.11 0.344 0.3198 1 22.384       
28 Control 0.314 0.302 0.012 0.344 0.0349 1 2.442       
29 Control 0.356 0.302 0.054 0.344 0.1570 1 10.988       
30 Control 0.369 0.302 0.067 0.344 0.1948 1 13.634       
31 Control 0.304 0.302 0.002 0.344 0.0058 1 0.407 9.1279 7.8639 2.9723 
1 
50 Aminophylline 
x2 0.371 0.302 0.069 0.344 0.2006 1 14.041       
2 
50 Aminophylline 
x2 0.362 0.302 0.06 0.344 0.1744 1 12.209       
3 
50 Aminophylline 
x2 0.379 0.302 0.077 0.344 0.2238 1 15.669       
4 
50 Aminophylline 
x2 0.361 0.302 0.059 0.344 0.1715 1 12.006       
5 
50 Aminophylline 
x2 0.309 0.302 0.007 0.344 0.0203 1 1.424       
6 
50 Aminophylline 
x2 0.403 0.302 0.101 0.344 0.2936 1 20.552       
7 
50 Aminophylline 
x2 0.498 0.302 0.196 0.344 0.5698 1 39.884       
8 
50 Aminophylline 
x2 0.406 0.302 0.104 0.344 0.3023 1 21.163 17.1185 11.0487 3.9063 
9 50 Amino + CCl4 0.565 0.302 0.263 0.344 0.7645 5 267.587       
10 50 Amino + CCl4 0.422 0.302 0.12 0.344 0.3488 5 122.093       
11 50 Amino + CCl4 0.489 0.302 0.187 0.344 0.5436 5 190.262       
12 50 Amino + CCl4 0.578 0.302 0.276 0.344 0.8023 5 280.814       
13 50 Amino + CCl4 0.347 0.302 0.045 0.344 0.1308 5 45.785       
14 50 Amino + CCl4 0.522 0.302 0.22 0.344 0.6395 5 223.837       
15 50 Amino + CCl4 0.384 0.302 0.082 0.344 0.2384 5 83.430       
16 50 Amino + CCl4 0.591 0.302 0.289 0.344 0.8401 5 294.041 188.4811 94.8566 33.5369 
17 0.025 ml/kg CCl4 0.846 0.302 0.544 0.344 1.5814 5 553.488       
18 0.025 ml/kg CCl4 0.673 0.302 0.371 0.344 1.0785 5 377.471       
19 0.025 ml/kg CCl4 0.71 0.302 0.408 0.344 1.1860 5 415.116       
20 0.025 ml/kg CCl4 0.492 0.302 0.19 0.344 0.5523 5 193.314       
21 0.025 ml/kg CCl4 0.797 0.302 0.495 0.344 1.4390 5 503.634       
22 0.025 ml/kg CCl4 0.507 0.302 0.205 0.344 0.5959 5 208.576       
23 0.025 ml/kg CCl4 1.025 0.302 0.723 0.344 2.1017 5 735.610       
24 0.025 ml/kg CCl4 0.857 0.302 0.555 0.344 1.6134 5 564.680 443.9862 184.6513 65.2841 
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Figure 18: Serum ALT Levels with Two Administrations of Aminophylline.  Adult male 
ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Results are expressed as mean ± 
SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were performed, 
with ** indicating a significant difference at p<0.01.  Administration of 50 mg/kg 
aminophylline at 30 and 60 minutes reduced the CCl4-induced increase in ALT levels 
greater than fifty percent.  
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 This experiment showed that it was possible for two intraperitoneal 
administrations of aminophylline (50 mg/kg) at 30 and 60 minute intervals following the 
intraperitoneal administration of CCl4 to significantly reduce (p < 0.01) the serum ALT 
levels.  Although the CCl4-induced elevation in serum ALT was diminished by 58%, the 
resulting levels were still indicative of some hepatocellular damage.  The belief that there 
may have been some hepatocellular damage may be supported by the relatively low ALT 
levels for the group administered only CCl4.  These results may have been lower than in 
the previous experiments, because the ALT standard solution may have degraded 
somewhat.  Even though the ALT standard had not yet expired, a new standard would be 
used in subsequent experiments.  Fortunately, ALT elevations are not as indicative of 
irreparable damage as other findings (e.g. LDH).  Although these serum ALT assay 
results do not reflect a complete reversion to those of the control groups, they do suggest 
that aminophylline, when administered twice is significantly hepatoprotective against 
CCl4. 
 The subsequent experiment tested whether the hepatoprotective results from the 
prior experiment, in which 50 mg/kg of aminophylline was administered thrice, at 30, 60 
and 90 minute intervals following intraperitoneal administration of 0.025 ml/kg of CCl4, 
were repeatable.  The reason for this is that these initial ALT assay results suggested that 
there was nearly a complete reversion to the control levels when both CCl4.and 
aminophylline were administered, and such a dosing regimen could be considered 
completely hepatoprotective.
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Table 17: Serum ALT Levels with Three Co-Treatments With Aminophylline.  The 
results of this experiment are displayed graphically in Figure 19 on the following page. 
   ALT  
No Treatment A505 Blank A-Bl Std-Bl (R)/Cal DF Conc Avg Std Dev Std Err 
1 Control 0.447 0.373 0.074 0.223 0.3318 1 23.229  
2 Control 0.414 0.373 0.041 0.223 0.1839 1 12.870  
3 Control 0.401 0.373 0.028 0.223 0.1256 1 8.789  
4 Control 0.374 0.373 0.001 0.223 0.0045 1 0.314  
5 Control 0.408 0.373 0.035 0.223 0.1570 1 10.987  
6 Control 0.376 0.373 0.003 0.223 0.0135 1 0.942  
7 Control 0.394 0.373 0.021 0.223 0.0942 1 6.592  
8 Control 0.404 0.373 0.031 0.223 0.1390 1 9.731 9.1816 7.2494 2.5631 
9 50 Animophylline x3 0.397 0.373 0.024 0.223 0.1076 1 7.534  
10 50 Animophylline x3 0.38 0.373 0.007 0.223 0.0314 1 2.197  
11 50 Animophylline x3 0.437 0.373 0.064 0.223 0.2870 1 20.090  
12 50 Animophylline x3 0.391 0.373 0.018 0.223 0.0807 1 5.650  
13 50 Animophylline x3 0.427 0.373 0.054 0.223 0.2422 1 16.951  
14 50 Animophylline x3 0.391 0.373 0.018 0.223 0.0807 1 5.650  
15 50 Animophylline x3 0.443 0.373 0.07 0.223 0.3139 1 21.973  
16 50 Animophylline x3 0.404 0.373 0.031 0.223 0.1390 1 9.731 11.2220 7.4297 2.6268 
17 50 Amino + CCl4 0.482 0.373 0.109 0.223 0.4888 5 171.076  
18 50 Amino + CCl4 0.598 0.373 0.225 0.223 1.0090 5 353.139  
19 50 Amino + CCl4 0.489 0.373 0.116 0.223 0.5202 5 182.063  
20 50 Amino + CCl4 0.418 0.373 0.045 0.223 0.2018 5 70.628  
21 50 Amino + CCl4 0.507 0.373 0.134 0.223 0.6009 5 210.314  
22 50 Amino + CCl4 0.445 0.373 0.072 0.223 0.3229 5 113.004  
23 50 Amino + CCl4 0.61 0.373 0.237 0.223 1.0628 5 371.973  
24 50 Amino + CCl4 0.507 0.373 0.134 0.223 0.6009 5 210.314 210.3139 105.4594 37.2855 
25 0.025 ml/kg CCl4 0.862 0.373 0.489 0.223 2.1928 5 767.489  
26 0.025 ml/kg CCl4 0.782 0.373 0.409 0.223 1.8341 5 641.928  
27 0.025 ml/kg CCl4 1.198 0.373 0.825 0.223 3.6996 5 1294.843  
28 0.025 ml/kg CCl4 1.047 0.373 0.674 0.223 3.0224 5 1057.848  
29 0.025 ml/kg CCl4 1.227 0.373 0.854 0.223 3.8296 5 1340.359  
30 0.025 ml/kg CCl4 0.803 0.373 0.43 0.223 1.9283 5 674.888  
31 0.025 ml/kg CCl4 1.292 0.373 0.919 0.223 4.1211 5 1442.377  
32 0.025 ml/kg CCl4 1.21 0.373 0.837 0.223 3.7534 5 1313.677 1066.676 327.8986 115.9297 
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Figure 19: Serum ALT Levels with Three Co-Treatments With Aminophylline.  Adult 
male ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Results are expressed as mean ± 
SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were performed, 
with ** indicating a significant difference at p<0.01.  Aminophylline (50 mg/kg) was 
administered via intraperitoneal injection 30, 60 and 120 minutes following 
intraperitoneal administration of CCl4. The three administrations of aminophylline 
reduced the CCl4-induced increase in serum ALT levels by roughly eighty percent.   
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This experiment suggests that the hepatoprotective effects of aminophylline 
observed in previous experiments were repeatable.  The relative diminution of CCl4-
induced increases in serum ALT was comparable in this experiment (81%) as was the 
case in the prior study with three administrations of aminophylline (also 81%).  There 
may, however be valid concerns about the safety of aminophylline, as a result of the 
observation of a potentially adverse effect in a prior experiment, although none were 
observed in the latest one. 
The serum ALT assay results strongly suggest that the intraperitoneal 
administration of aminophylline is extremely protective against the free radical-mediated 
hepatotoxicity caused by carbon tetrachloride.  The increase in serum ALT levels as a 
result of 0.025 ml/kg intraperitoneal administration of carbon tetrachloride is roughly 
100-fold. The reason for this is that structurally intact and viable hepatocytes do not 
normally release this intracellular enzyme into the interstitial fluid.  This protective effect 
of aminophylline appears to be dose-dependent, as the three administrations of 50 mg/kg 
aminophylline are much more effective than two administrations, abstaining from the 
two-hour post-toxicant interval, with average reductions in ALT of approximately eighty 
percent and fifty percent, respectively.  By administering lesser concentrations three 
times, it may reduce the potential for any adverse effects due to aminophylline. 
 
TBARS Assay 
 The results from the experiment, in which three 50 mg/kg intraperitoneal dosages 
of aminophylline reduced the serum ALT levels elevated due to CCl4.by 80 percent, 
 94
raised questions as to the mechanism by which this occurred.  In the following 
experiment, the thiobarbituric acid reactive substances (TBARS) assay was conducted to 
determine the extent of lipid peroxidation caused by 0.025 ml/kg carbon tetrachloride and 
prevented by two 50 mg/kg dosages of aminophylline.  The controls utilized in this 
experiment were also utilized from a similar study, in which the dilution in phosphate 
buffered saline was one part liver tissue in ten parts total, or one part in nine parts saline.  
The remaining samples were diluted one part to ten, which resulted in a dilution factor of 
eleven, compared to ten for the controls.  The samples from mice treated with carbon 
tetrachloride and aminophylline yielded MDA equivalent levels comparable to the 
controls, whereas carbon tetrachloride elevated MDA equivalent levels three-fold.  This 
indicates that aminophylline may protect against the production of lipid peroxides as a 
result of carbon tetrachloride.
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Table 18: Standards for TBARS Assay.  Results of this portion of the TBARS assay are 
listed in the standard curve below. 
  
TBARS   Calibration Curve 
Sample MDA Equiv. A532 
A 0 0.003 
B 1 0.032 
C 2 0.079 
D 3 0.176 
E 4 0.215 
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Figure 20: Standard Curve for TBARS Assay.  
This standard curve was established to determine the extent of lipid peroxidation, in 
MDA equivalents, of the samples.  The TBARS results for these samples are on the 
following page.
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Table 19: Hepatic Lipid Peroxidation Levels With Two Dosages of Aminophylline.  The 
results of this TBARS assay are displayed graphically in Figure 21 on the following page. 
  TBARS ,             
No Treatment A532 Conc. DF MDA  Avg 
Std 
Dev 
Std 
Err 
C1 Control 0.258 4.942 10 49.419       
C2 Control 0.292 5.601 10 56.008 52.713 4.659 3.295 
1 50 Animo x2 0.291 5.581 11 61.395       
2 50 Animo x2 0.195 3.721 11 40.930       
3 50 Animo x2 0.294 5.640 11 62.035       
4 50 Animo x2 0.227 4.341 11 47.752       
5 50 Animo x2 0.317 6.085 11 66.938       
6 50 Animo x2 0.313 6.008 11 66.085       
7 50 Animo x2 0.282 5.407 11 59.477       
8 50 Animo x2 0.191 3.643 11 40.078 55.586 10.995 3.887 
9 CCl4+Amino 0.282 5.407 11 59.477       
10 CCl4+Amino 0.268 5.136 11 56.492       
11 CCl4+Amino 0.224 4.283 11 47.112       
12 CCl4+Amino 0.32 6.143 11 67.578       
13 CCl4+Amino 0.22 4.205 11 46.260       
14 CCl4+Amino 0.173 3.295 11 36.240       
15 CCl4+Amino 0.27 5.174 11 56.919       
16 CCl4+Amino 0.254 4.864 11 53.508 52.948 9.586 3.389 
17 0.025 CCl4 0.789 15.233 11 167.558       
18 0.025 CCl4 1.215 23.488 11 258.372       
19 0.025 CCl4 0.959 18.527 11 203.798       
20 0.025 CCl4 0.787 15.194 11 167.132       
21 0.025 CCl4 0.834 16.105 11 177.151       
22 0.025 CCl4 0.696 13.430 11 147.733       
23 0.025 CCl4 0.74 14.283 11 157.112       
24 0.025 CCl4 0.554 10.678 11 117.461 174.540 41.875 14.805 
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Figure 21: Hepatic Lipid Peroxidation Levels With Two Dosages of Aminophylline.  
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  Results are expressed as 
mean ± SEM.  Two-sample unequal variance (heteroscedastic) one-way T-tests were 
performed, with ** indicating a significant difference at p<0.01.  The administration of 
50 mg/kg aminophylline at 30 and 60 minutes following CCl4 reduced the CCl4-induced 
increases in MDA equivalents to levels comparable to the controls.  
 98
 The results of this hepatic tissue TBARS assay showed that aminophylline, 
administered in two 50 mg/kg dosages was able to significantly (p < 0.01) reduce the free 
radical damage caused by CCl4.  The results of this experiment beg the question as to 
whether PARP inhibition may be the primary hepatoprotective mechanism of 
aminophylline.  Perhaps it could entail phosphodiesterase inhibition or some other means 
of preventing lipid peroxidation.  Regardless of which of the multitude of mechanisms of 
action attributed to aminophylline is the major cause of its hepatoprotective effects, it is 
clear that the extent of free radical hepatocellular damage caused by CCl4 is significantly 
reduced. 
 
Histopathological Staining / Immunohistochemistry 
 The results of the histopathology strongly suggest that aminophylline protects 
against both the necrotic and apoptotic responses of the hepatocytes to carbon 
tetrachloride.  The hematoxylin and eosin staining, along with the TUNEL and cleaved 
caspase-3 slides for two of the three random samples from mice, which were 
administered intraperitoneal injections of carbon tetrachloride (0.025 ml/kg) and the three 
administrations of aminophylline, were indistinguishable from the control samples.  The 
samples from one of the mice, which was treated with carbon tetrachloride and 
aminophylline, did reflect minimal damage. However the extent of this was not 
comparable to that observed in mice that received carbon tetrachloride alone.  The mice 
who were administered only carbon tetrachloride displayed widespread necrotic zones in 
the centrilobular regions, along with minimal positive results for the TUNEL (one 
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response was strong) and cleaved caspase-3 immunohistochemistry.  As was expected, 
there were no detectable histopathological damages to the livers of mice receiving only 
aminophylline
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Table 20: Results of Histopathological Assessments for CCl4 and Aminophylline 
Treatments. 
 
Grading of histopathologic staining /immunohistochemistry was as follows: 
 
H&E: presence or absence of necrosis and its location (e.g. centrilobular, periportal) 
 
TUNEL: Apoptotic Index based on the percentage/intensity of apoptotic cells, from 0-3 
0%/none = 0;       1-25%/mild = 1;       26-50%/moderate = 2;       >50%/prominent = 3 
 
Cleaved caspase-3: Percent of cells testing positive for cleaved (activated) caspase-3 
using immunohistochemistry, from 0-4. 
0% = 0;              1-25% = 1;              26-50% = 2;              51-75% = 3;              >75% = 4. 
  Histopathology   Grading    
ID 
# Treatment Group Hematoxylin & Eosin TUNEL Cleaved Caspase-3 
2 Control Normal 0 0 
5 Control Normal 0 0 
7 Control Normal 0 0 
11 Aminophylline Normal 0 0 
12 Aminophylline Normal 0 0 
14 Aminophylline Normal 0 0 
18 CCl4 & Aminophylline Normal 0 0 
22 CCl4 & Aminophylline Normal 0 0 
23 CCl4 & Aminophylline Centrilobular Necrosis 1 1 
28 CCl4 Centrilobular Necrosis 1 1 
29 CCl4 Centrilobular Necrosis 1 1 
31 CCl4 Centrilobular Necrosis 3 1 
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Figure 22: Hematoxylin and Eosin Staining Results: Control Treatment.  Adult male ICR 
mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Hematoxylin is the blue stain for 
positively charged molecules (e.g. DNA).  Eosin is the pink counterstain for negatively 
charged molecules (e.g. protein).  There were no necrotic zones found in this 
photographed slide, or for the other samples from control mice receiving only corn oil 
and saline, that were visually confirmed under the microscope, but not photographed due 
to resource constraints.  These findings confirm the low ALT values in serum from mice 
in this treatment group, in that there was no damage to the liver.
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Figure 23: Hematoxylin and Eosin Staining Results: Aminophylline Treatment.  Adult 
male ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  Hematoxylin is the blue stain for 
positively charged molecules (e.g. DNA).  Eosin is the pink counterstain for negatively 
charged molecules (e.g. protein).  There were no necrotic zones found in this 
photographed slide, or for the other samples from mice receiving only corn oil and 
aminophylline, that were visually confirmed under the microscope, but not photographed 
due to resource constraints.  These findings confirm the low ALT values in serum from 
mice in this treatment group, comparable to those of the controls, meaning that 
aminophylline does not cause liver damage.
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Figure 24: Hematoxylin and Eosin Staining Results: Aminophylline and Carbon 
Tetrachloride Treatment.  Adult male ICR mice with an average weight of 30 grams were 
sacrificed 24 hours following intraperitoneal administration of carbon tetrachloride.  
Hematoxylin is the blue stain for positively charged molecules (e.g. DNA).  Eosin is the 
pink counterstain for negatively charged molecules (e.g. protein).  The majority of the 
samples from mice that were administered carbon tetrachloride and aminophylline 
displayed no indication of a necrotic response, as indicated in this slide.  These results 
were comparable to those of the controls.
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Figure 25: Hematoxylin and Eosin Staining Results: Carbon Tetrachloride Treatment.  
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  Hematoxylin is the blue 
stain for positively charged molecules (e.g. DNA).  Eosin is the pink counterstain for 
negatively charged molecules (e.g. protein).  This group of mice received only carbon 
tetrachloride and saline, without aminophylline or any other PARP inhibitor.  There 
appears to be a substantial necrotic response surrounding the central vein, as is reflected 
by the absence of intact cells.  This slide confirms that elevations in serum ALT levels 
observed for this treatment group were indicative of irreversible hepatocellular damage.
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Figure 26: TUNEL Staining Results: Control Treatment.  Adult male ICR mice with an 
average weight of 30 grams were sacrificed 24 hours following intraperitoneal 
administration of carbon tetrachloride.  TUNEL stains for the presence of DNA double 
strand cleavage which is specifically associated with apoptosis, a form of controlled cell 
death.  Grading of histopathologic staining was as follows: 
TUNEL: Apoptotic Index based on the percentage/intensity of apoptotic cells, from 0-3 
0%/none = 0;       1-25%/mild = 1;       26-50%/moderate = 2;       >50%/prominent = 3 
The Apoptotic Index of this sample is 0.  As was the case with the correspondingly low 
ALT levels for this treatment group, there was no evidence of hepatocellular injury.
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Figure 27: TUNEL Staining Results: Aminophylline Treatment.  Adult male ICR mice 
with an average weight of 30 grams were sacrificed 24 hours following intraperitoneal 
administration of carbon tetrachloride.  TUNEL stains for the presence of DNA double 
strand cleavage which is specifically associated with apoptosis.  This slide is 
representative of the group that received corn oil and aminophylline, and no carbon 
tetrachloride.  Grading of histopathologic staining was as follows: 
TUNEL: Apoptotic Index based on the percentage/intensity of apoptotic cells, from 0-3 
0%/none = 0;       1-25%/mild = 1;       26-50%/moderate = 2;       >50%/prominent = 3 
The Apoptotic Index of this sample is 0.  As was the case with the correspondingly low 
ALT levels for this treatment group, there was no evidence of hepatocellular injury.
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Figure 28: TUNEL Staining Results: Aminophylline and Carbon Tetrachloride 
Treatment.  Adult male ICR mice with an average weight of 30 grams were sacrificed 24 
hours following intraperitoneal administration of carbon tetrachloride.  TUNEL stains for 
the presence of DNA double strand cleavage which is specifically associated with 
apoptosis.  Grading of histopathologic staining was as follows: 
TUNEL: Apoptotic Index based on the percentage/intensity of apoptotic cells, from 0-3 
0%/none = 0;       1-25%/mild = 1;       26-50%/moderate = 2;       >50%/prominent = 3 
The Apoptotic Index of this sample is 0.The majority of the samples from mice that were 
administered carbon tetrachloride and aminophylline displayed no positive cells.  There 
was no evidence of hepatocellular injury in the majority of mice in this treatment group. 
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Figure 29: TUNEL Staining Results: Carbon Tetrachloride Treatment.  Adult male ICR 
mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  TUNEL stains for the presence of 
DNA double strand cleavage which is specifically associated with apoptosis, for the 
group receiving only carbon tetrachloride and saline.  Grading was as follows: 
TUNEL: Apoptotic Index based on the percentage/intensity of apoptotic cells, from 0-3 
0%/none = 0;       1-25%/mild = 1;       26-50%/moderate = 2;       >50%/prominent = 3 
The Apoptotic Index of this sample is 3, which is reflective of the strong or prominent 
apoptotic response, which is indicative of irreversible hepatocellular damage that 
corresponds with the elevated ALT levels for the mice in this treatment group.
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Figure 30: Cleaved Caspase-3 Immunohistochemistry Results: Control Treatment.  Adult 
male ICR mice with an average weight of 30 grams were sacrificed 24 hours following 
intraperitoneal administration of carbon tetrachloride.  The histopathology results for this 
immunohistochemical stain are reflected in this picture.  The cleavage and activation of 
caspase-3 is a committed step toward apoptosis.  Grading of the immunohistochemistry 
was as follows: 
Cleaved caspase-3: Percent of cells testing positive for cleaved (activated) caspase-3 
using immunohistochemistry, from 0-4. 
0% = 0;              1-25% = 1;              26-50% = 2;              51-75% = 3;              >75% = 4. 
This sample received a grade of 0, indicating the lack of hepatic damage among controls.
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Figure 31: Cleaved Caspase-3 Immunohistochemistry Results: Aminophylline Treatment.  
Adult male ICR mice with an average weight of 30 grams were sacrificed 24 hours 
following intraperitoneal administration of carbon tetrachloride.  The histopathology 
results for this immunohistochemical stain are reflected in this picture.  The cleavage and 
activation of caspase-3 is a committed step toward apoptosis.  Grading was as follows: 
Cleaved caspase-3: Percent of cells testing positive for cleaved (activated) caspase-3 
using immunohistochemistry, from 0-4. 
0% = 0;              1-25% = 1;              26-50% = 2;              51-75% = 3;              >75% = 4. 
This sample received a grade of 0, indicative of the lack of hepatic damage in mice 
administered aminophylline.
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Figure 32: Cleaved Caspase-3 Immunohistochemistry Results: Aminophylline and 
Carbon Tetrachloride Treatment.  Adult male ICR mice with an average weight of 30 
grams were sacrificed 24 hours following intraperitoneal administration of carbon 
tetrachloride.  The cleavage and activation of caspase-3 is a committed step toward 
apoptosis.  Histopathologic grading for this immunohistochemistry was as follows: 
Cleaved caspase-3: Percent of cells testing positive for cleaved (activated) caspase-3 
using immunohistochemistry, from 0-4.  This sample received a grade of 0. 
0% = 0;              1-25% = 1;              26-50% = 2;              51-75% = 3;              >75% = 4. 
The majority of the samples from mice from this group displayed no positive cells, 
confirming that aminophylline is an effective co-treatment against carbon tetrachloride.
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Figure 33: Cleaved Caspase-3 Immunohistochemistry Results: Carbon Tetrachloride 
Treatment.  Adult male ICR mice with an average weight of 30 grams were sacrificed 24 
hours following intraperitoneal administration of carbon tetrachloride.  The cleavage and 
activation of caspase-3 is a committed step toward apoptosis.  Histopathologic grading 
for this immunohistochemistry was as follows: 
Cleaved caspase-3: Percent of cells testing positive for cleaved (activated) caspase-3 
using immunohistochemistry, from 0-4. 
0% = 0;              1-25% = 1;              26-50% = 2;              51-75% = 3;              >75% = 4. 
This sample received a grade of 1. 
As expected, mice administered carbon tetrachloride had evidence of apoptosis.
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          In one of the mice receiving carbon tetrachloride and aminophylline, there were 
unexpected results.  This single mouse showed necrosis and apoptosis.  There are a 
number of possible explanations for the occurrence of necrosis and apoptosis in one of 
the mice receiving carbon tetrachloride and aminophylline.  The primary reason is most 
likely related to the use of outbred ICR mice.  In inbred mice, the genetic relatedness is 
higher than normal littermates (0.5, or 50% of genes are common), to the point where it 
approaches 1 (100% common genes), which is indicative of identical twins or clones.  
Outbred mice in the numbers used in these experiments were of such numbers, that they 
could not have originated from the same litter.  The significance of this is that unlike 
inbred mice, outbred mice may not always yield the same results as a result of differing 
genes. Therefore it would be expected that there would be some variation in the response 
to the toxicant and/or the co-treatment. 
 
In Vivo Conclusions 
 The in vivo results, although independent from their in vitro counterparts, 
similarly suggest that PARP inhibitors protect against carbon tetrachloride-induced 
hepatotoxity.  The serum ALT assays show that the intraperitoneal administration of CCl4 
significantly increases the levels of ALT in the serum, strongly suggestive of 
hepatocellular damage.  When aminophylline, a non-specific PARP inhibitor, was 
administered via intraperitoneal injection after the toxicant, the 100-fold increases in 
ALT were reduced by eighty percent.  The administration of CCl4 by intraperitoneal 
injection significantly increased lipid peroxidation three-fold, as evidenced by the 
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TBARS assay results.  The co-treatment with aminophylline significantly reduced the 
extent of lipid peroxidation.  Administration of CCl4 resulted in histopathology findings 
indicative of centrilobular necrosis and apoptosis.  Histopathology findings for the 
majority of the mice administered CCl4 followed by aminophylline were negative for 
necrosis and apoptosis.  The results complement each other in that the histopathology 
expands upon the nature and extent of damage caused by CCl4 and mitigated by 
aminophylline, as evidenced in the ALT assays.  This is because elevated ALT levels can 
be caused by sources other than from the liver (e.g. kidney, pancreas, heart and skeletal 
muscle) and may merely reflect reversible damage.  In contrast, the histopathology 
indicates the presence of non-reversible damage specifically in the liver.  Increases in 
ALT values may be indicative of temporary loss of hepatocellular membrane integrity.  
The indicators of apoptosis, DNA fragmentation (TUNEL) and cleavage of caspase-3 
(immunohistochemistry), are indicative of committed steps toward programmed cell 
death.  Similarly, the necrosis observed in the hematoxylin and eosin staining is 
irreversible.  Because of these results, one can conclude that aminophylline, a non-
specific PARP inhibitor, can effectively protect the liver against the free radical, non 
glutathione-mediated hepatotoxic effects of CCl4.  In short, aminophylline may be an 
effective treatment against exposure to carbon tetrachloride. 
 
Summary of Findings 
 The in vitro and in vivo results independently associate CCl4 with hepatic damage, 
and suggest that the use of PARP inhibitors mitigates that damage.  Although these 
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results can not be directly correlated to one another, they each serve a purpose in that 
they provide information as to the mechanism of action of PARP inhibitors, as well as the 
phenomenological data critical to the use of PARP inhibitors to prevent hepatic damage. 
Ideally, the same assays would have been used for both the in vitro and in vivo assays.  In 
the case of the latter, there was a concern that there would not be enough serum to 
conduct both ALT and LDH assays.  Since earlier experiments using ALT have shown 
elevations as a result of administration of CCl4, there was no question as to the sensitivity 
of this test, thus the serum was reserved for ALT tests, and no further LDH assays were 
conducted.  Although the in vitro and in vivo tests were not the identical assays, they all 
yielded similar results, in that the use of CCl4, either in the culture media or through 
intraperitoneal injections, resulted in substantial findings of hepatic damage.  Likewise 
the use of a PARP inhibitor with the CCl4 significantly reduced the extent of the carbon 
tetrachloride-induced damage.  In conclusion, these experiments strongly indicate that the 
use of PARP inhibitors, such as 6(5H)-phenanthridinone and aminophylline can protect 
against the damage caused by carbon tetrachloride.  This research is significant in that it 
may provide a means to protect against other free radical-mediated and glutathione-
independent hepatotoxicants in humans. 
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In Vitro Findings 
 Introduction of CCl4 to the culture media for HepG2 cells 
significantly increases relative LDH levels in the culture media. 
 Co-treatment of HepG2 cells with 6(5H)-phenanthridinone 
significantly reduces the CCl4-induced increases in relative LDH 
levels in the culture media. 
 Introduction of CCl4 into the culture media with HepG2 cells 
significantly increases PARP Activity. 
 Co-treatment of HepG2 cells with 6(5H)-phenanthridinone 
significantly reduces the CCl4-induced increases in PARP 
activity. 
In Vivo Findings 
 Intraperitoneal administration of ICR mice with CCl4 
significantly increases serum ALT levels. 
 Subsequent intraperitoneal administration of ICR mice with 
aminophylline significantly reduced the CCl4mediated 
elevations in serum ALT levels. 
 Intraperitoneal administration of ICR mice with CCl4 
significantly increases lipid peroxidation in the liver. 
 Subsequent intraperitoneal administration of ICR mice with 
aminophylline significantly reduced the CCl4mediated 
elevations in lipid peroxidation. 
 Intraperitoneal administration of ICR mice with CCl4 results in 
substantial centrilobular necrotic and apoptotic responses in liver 
tissue. 
 Subsequent intraperitoneal administration of ICR mice with 
aminophylline eliminated or reduced the presence of necrosis 
and apoptosis in the liver. 
 
Figure 34: Summary of Experimental Findings.
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Chapter Five 
Discussion 
 
The results of the previously discussed experiments make a strong case for the 
protective role of PARP inhibitors in general, and specifically aminophylline, against 
carbon tetrachloride-induced hepatotoxicity.  The issue of correlation between the in vitro 
and in vivo experimental results also warrants some discussion. 
 Aside from a general discussion and summation of the experimental results, there 
are other matters of importance.  Two major themes, which warrant further discussion in 
light of the experiments reported in this dissertation, are the impact of this research on 
public health and the avenues for future study.  Lastly, the conclusion summarizes and 
stresses the importance of the experimental findings. 
 
Explanation of Experimental Findings 
 The following is a summary of the experimental results.  These results are 
addressed in this section in the same general order as the materials and methods section 
and the results.  The in vitro portion of these experiments is further divided into the LDH 
assay results and PARP activity assay results.  The in vivo portion of these experiments is 
subdivided into ALT assay results, TBARS assay results and histopathology findings.  
The primary PARP inhibitor used in the in vitro portion of these experiments is 6(5H)-
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phenanthridinone, and the main PARP inhibitor used in the in vivo experiments is 
aminophylline.   
 The in vitro findings using 6(5H)-phenanthridinone as a co-treatment show that, 
at concentrations below 40 µM, this PARP inhibitor can protect against carbon 
tetrachloride-induced hepatotoxicity, without adversely affecting the metabolic activity of 
the hepatocytes.  The protection against hepatotoxic effects is evidenced by the 
significant diminution in lactate dehydrogenase (LDH) activity in the culture media for 
cells receiving both treatments versus those exposed only to carbon tetrachloride.  Further 
studies measuring the activity of PARP resulted in significant reductions in PARP 
activity when 6(5H)-phenanthridinone was co-administered compared to when carbon 
tetrachloride was the only treatment.  This diminution in PARP activity is critical, as 
excessive activity can lead to NAD and ATP depletion, which can result in necrosis.   
Lactate dehydrogenase is an intracellular enzyme, that if found in the culture 
medium, is associated with the loss of membrane integrity.  As was displayed in Figure 1, 
lipids are common targets of the free radicals generated as a result of the dehalogenation 
of carbon tetrachloride.  The phospholipids that constitute cell membranes are no 
exception to this rule.  The relative LDH levels were significantly elevated as a result of 
the exposure to carbon tetrachloride in the culture media, which suggests that carbon 
tetrachloride damages the hepatocytes, resulting in the release of LDH, an intracellular 
enzyme, into the culture media.  The co-administration of the cell culture media with 
6(5H)-phenanthridinone resulted in the reduction of the relative LDH levels by fifty 
percent. 
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The fact that the LDH activity was only reduced roughly fifty percent may be as 
much a function of the solubility of 6(5H)-phenanthridinone as any other factor.  In order 
to completely solubilize 6(5H)-phenanthridinone, one has to use pure dimethyl sulfoxide 
(DMSO) as a solvent.  In my experiments, the 6(5H)-phenanthridinone was solubilized in 
pure DMSO, and then a small amount of this solution was added to the media, resulting 
in a colloidal mixture.  The use of DMSO was minimized because it is known to inhibit 
PARP by itself.  Furthermore, the United States Food and Drug Administration (FDA) 
has reported hepatotoxic effects of topical administration of DMSO. 
 The ultimate test as to whether PARP plays a role in the reduction in carbon 
tetrachloride-induced hepatotoxicity by 6(5H)-phenanthridinone is the PARP activity 
assay.  The incorporation of soluble carbon-14 radiolabeled NAD into insoluble poly 
ADP-ribose is used to assess the activity of PARP.  The significant reduction in PARP 
activity by 6(5H)-phenanthridinone strongly suggests that its hepatoprotective effects are 
directly related to PARP inhibition.  The presence of identical DMSO concentrations in 
the cell media for all treatments eliminates it as a variable.  Given these in vitro results, 
there is reason to believe that the co-administration of one or more PARP inhibitors could 
minimize the free radical-mediated hepatotoxic effects of carbon tetrachloride. 
 The prior in vitro results confirming the hepatoprotective effects of 6(5H)-
phenanthridinone would lead one to believe that it would be effective against the 
hepatotoxic effects of carbon tetrachloride in vivo.  Although it should be possible to 
inject a solution of 6(5H)-phenanthridinone in pure DMSO, colloidal suspensions created 
by diluting these solutions in saline or deionized water do not allow for reliable 
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administration.  These difficulties have been resolved by Pacher et al (2002), who utilized 
PJ34, a water soluble derivative of 6(5H)-phenanthridinone, to inhibit PARP.  
Nicotinamide (niacinamide) was also found to reduce the hepatotoxic effects of carbon 
tetrachloride in male ICR mice, however these results merely confirmed previous 
findings, likely made before nicotinamide was found to inhibit PARP.  Although it would 
be intriguing to determine the primary mechanism by which nicotinamide is 
hepatoprotective, whether it is through PARP inhibition, its incorporation into additional 
NAD used by PARP, or some antioxidant capability, the fact that it has been previously 
shown to be efficacious was sufficient knowledge for those who reported the initial 
findings, as it was here.  There were numerous other PARP inhibitors, which could be 
administered to test their hepatoprotective effects, among them aminophylline. 
Aminophylline has been reported to inhibit the activity of poly (ADP-ribose) 
polymerase-1 (PARP-1), and is currently used as an anti-asthmatic medication. Increases 
in PARP-1 activity have been associated with chemical-induced cellular damage. The 
purpose of this study was to determine whether aminophylline can protect against free 
radical-mediated hepatotoxicity, as is caused by carbon tetrachloride (CCl4). Male ICR 
mice were administered 0.025ml/kg of CCl4.  CCl4-treated mice developed 
hepatotoxicity, as evidenced by a 100fold increase in serum alanine aminotransferase 
(ALT) levels. Also, a significant increase in hepatic malondialdehyde (MDA) equivalents 
was measured. These effects were corroborated by histopathological findings of minimal 
to strong necrosis and apoptosis, the former as evidenced via hematoxylin and eosin 
(H&E) staining, and the latter by terminal deoxynucleotidyl transferase biotin-dUTP nick 
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end labeling (TUNEL) and cleaved caspase-3 immunohistochemistry. Administration of 
aminophylline reduced ALT levels roughly eighty percent, MDA levels were decreased 
by seventy percent and necrosis was eliminated.  Also treatment with aminophylline 
resulted in only slight changes in hepatocyte cytoplasm and maximum changes were seen 
at twenty-four hours following aminophylline treatment. These studies indicate that 
aminophylline treatment can inhibit CCl4-induced hepatotoxicity. 
 Aminophylline, when administered via intraperitoneal injection thrice at thirty, 
sixty and one hundred twenty minutes following a single carbon tetrachloride injection, 
was proven to reduce the hepatotoxic effects of carbon tetrachloride.  This is evident 
from the ALT results and the examination of histopathology samples.  The 
hepatoprotective effect of aminophylline appears to work in a dose-response fashion, 
because, despite the statistically significant reduction in ALT with two intraperitoneal 
administrations of 50 mg/kg aminophylline, the percentage of the reduction was less than 
with three doses.  The TBARS assays yielded significant reductions in malondialdehyde 
equivalents when aminophylline was administered twice.  It may have done the same for 
three administrations, except that difficulty in establishing a calibration curve on the 
latter occasion made this difficult to confirm.  The reduction in malondialdehyde 
equivalents in the TBARS assay is reflective of a reduction in lipid peroxidation.  
Collectively, these results strongly suggest that aminophylline, administered via 
intraperitoneal injection, is protective against the hepatotoxic effects of carbon 
tetrachloride in male ICR mice, even when this co-treatment is administered after the 
toxicant. 
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 Aminophylline was an intriguing choice as a co-treatment, as it has been 
approved by the FDA for the treatment of asthmatic patients.  Although it may be 
difficult to titrate the dosage and assess the efficacious and/or adverse effects of 
aminophylline, it is possible to do so in a clinical setting.  Since aminophylline is water 
soluble, it became much easier to administer a consistent and reliable dosage, which was 
not the case for other PARP inhibitors, such as 6(5H)-phenanthridinone, benzamide and 
the various aminobenzamides.  Aminophylline disassociates readily in the bloodstream 
into its constituents, two molecules of theophylline and one molecule of ethylene 
diamine.  Since aminophylline and theophylline are well known to emergency room 
physicians, there is also likely to be a general understanding as to how it can be 
administered safely.  This makes it all the more likely to be accepted as an antidote in the 
event of an accidental overexposure, if other studies can confirm its efficacy.  When 
aminophylline or theophylline is administered to alleviate acute asthmatic symptoms, the 
dosage often has to be titrated to the appropriate level.  Therefore, the selection of time 
periods for the intraperitoneal administration of aminophylline, thirty, sixty and one 
hundred twenty minutes following the intraperitoneal administration of carbon 
tetrachloride were done in part to mimic an emergency room response.  Had 
aminophylline only been effective if administered prior to, or concomitant with, carbon 
tetrachloride, it would have been inconsistent with emergency room care.  Furthermore, it 
would be unreasonable to keep workers on prophylactic medications, particularly those 
with the potential for adverse effects of their own.  The reason for this is that such 
pharmacological measures that are supposed to be protective of employees should pose 
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any undue risks to them in and of themselves. 
 In summation, CCl4 is a model hepatotoxicant that produces free radical-mediated 
hepatic damage, as evidenced via elevated serum transaminases, lipid peroxidation and 
histopathologic changes.  Aminophylline (50 mg/kg), administered via intraperitoneal 
injection, at intervals of thirty, sixty and ninety minutes following intraperitoneal 
administration of CCl4 (0.025 ml/kg), significantly reduced the hepatotoxic effects of the 
toxicant in male ICR mice.  This is confirmed in this study, in the form of significantly 
reduced ALT levels in the serum, significantly fewer malondialdehyde equivalent 
concentrations, and differences in H&E, TUNEL and cleaved caspase-3 
immunohistochemical analyses.  These findings suggest that aminophylline may be 
similarly efficacious against other free radical-mediated hepatotoxicants. 
 
Impact on Public Health 
The results of these experiments strongly suggest that aminophylline has the 
potential to block the free radical-mediated hepatotoxicity of carbon tetrachloride.  Some 
might argue that, since the end use of carbon tetrachloride, particularly as a fumigant, has 
been dramatically reduced by the United States and other parties as part of the Montreal 
Protocol for possible ozone depleting characteristics, that there is no real issue of impact 
on public health.  There are three reasons, however why the results of these experiments 
still have the potential for a positive impact on public health; (1) the likelihood for 
exposure during remediation of contaminated sites, (2) that carbon tetrachloride is still 
used as an intermediate in the production of other compounds, and (3) that carbon 
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tetrachloride is a model hepatotoxicant, with a similar mechanism of action to other free 
radical-mediated, non-glutathione dependent toxicants. 
There is still a significant likelihood of human contact with carbon tetrachloride.  
The presence of a specific chemical at waste sites is based on two factors, the 
extensiveness of its use and disposal, and the kinetics of its degradation.  The 
Environmental Protection Agency has reported the presence of carbon tetrachloride in at 
least 423 of the 1,636 sites on the National Priority List.  As a result, there is a significant 
potential for exposure among workers cleaning up the waste sites, which can only be 
prevented by the proper use of personal protective equipment. 
Carbon tetrachloride was widely used in the United States as a dry cleaning 
solvent, and in other commercial applications.  Although many countries have largely 
curtailed the use of carbon tetrachloride, many of the developing countries which were 
not signatories to the Montreal Protocol may continue to use it. 
The theory that CCl4 depletes the ozone layer seem to defy logic, given the 
physical properties of this chemical.  CCl4 has a vapor pressure (91.3 mm Hg at 20 °C) 
which allows for significant volatilization, with a molecular weight of 153.8 and a vapor 
density of 5.32, suggesting that CCl4 vapors would be expected to remain at low altitudes, 
however some scientists must assume it can reach the upper atmosphere.  In the event 
that carbon tetrachloride volatilizes, it is fairly persistent, with estimated presence in the 
trophosphere or stratosphere from 30 to 100 years (Galbally, 1976; Lovelock, 1977; 
Simmonds et al. 1983, 1988; Singh et al. 1979).  As such, environmentalists fear the 
potential for depletion of the ozone layer as a result of carbon tetrachloride releases. 
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The phasing out of CCl4 as an end use product does not preclude the potential for 
human exposure.  The synthesis of complex organic compounds is based on the ability to 
use components with leaving groups, and attach them to each other, creating new end use 
products.  Ironically, one of these end use compounds, perchlorethylene, has replaced 
CCl4 as the principal dry cleaning solvent.  As a result, carbon tetrachloride is still a 
critical compound, albeit indirectly, to the dry cleaning industry.  Carbon tetrachloride 
was also commonly used to produce chlorofluorocarbon refrigerants, such as 
trichlorofluoromethane and dichlorodifluromethane, (HSDB, 2003).  As such a 
substantial amount of CCl4 is still being manufactured.  The two remaining American 
facilities producing carbon tetrachloride in Louisiana and Kansas have annual capacities 
of 90 million and 20 million pounds, respectively (HSDB. 2003).  
 Carbon tetrachloride is referred to as a model hepatotoxicant because its 
mechanism of action is comparable to that of similar compounds.  There are a number of 
halocarbons, the metabolites of which can potentially cause free radical damage. Also 
some alcohols (e.g. allyl alcohol) have the potential to cause free radical-mediated 
hepatotoxicity, and can in some cases (e.g. alcohol and acetaminophen) alter the 
mechanism of toxicity, so that free radicals are generated.  Of this wide array of 
chemicals, carbon tetrachloride has arguably the most potential for adverse effects at a 
given dosage, because the trichloromethyl radical generated through the reductive effects 
of cytochrome P-450 (specifically CYP2E1) is particularly effective in causing free 
radical damage.  This may be largely due to the significant partial positivity of the carbon 
atom, which is caused by the electronegativity of the three chloride molecules, with 
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which the carbon atom shares six of the seven electrons.  By using model toxicants, such 
as carbon tetrachloride, it may be possible to focus on finding a number of antidotes for 
entire classes of compounds based on their mechanisms of action.  The experiments in 
this dissertation were performed with the purpose of finding out whether one or more 
PARP inhibitors are capable of protecting the liver from the free radical-mediated, non-
glutathione dependent hepatotoxic effects of carbon tetrachloride, with the potential to 
protect against additional compounds with the same or similar mechanisms of 
hepatotoxicity. 
 In summation, carbon tetrachloride is still a chemical of concern at a number of 
sites, and poses significant health risks.  Environmental Defense lists carbon tetrachloride 
as one of the eight hazardous air pollutants, which collectively contribute to 99% of total 
hazardous air pollutant-associated cancer risks (scorecard.org).  Carbon tetrachloride is 
the third highest compound contributing to cancer risks, with an added cancer risk 
contribution of 5%.  Given the former widespread use of carbon tetrachloride, and the 
persistence and hepatotoxicity of carbon tetrachloride, any effort to minimize its 
hazardous effects has the potential to benefit mankind. 
 
Possible Future Studies 
 The experiments conducted in this dissertation establish the foundation for a 
number of opportunities for further study.  These involve the use of different types of 
experimental animals, alternate forms of dosage or routes of exposure, expanded in vitro 
experimentation, different types of free radical-mediated hepatotoxicants and the testing 
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of compounds with completely different mechanisms of toxicity (e.g. Aryl Hydrocarbon 
receptor binding, glutathione oxidation or conjugation). 
 In order to confidently assume that, prior to testing in humans, a compound would 
be both efficacious and safe at efficacious doses, experimentation in additional species 
and subspecies of animals is required.  Although much is known about the toxicity of 
aminophylline and theophylline in humans, the efficacious dosage will have to be 
estimated, at least until anecdotal reports of their usage for this purpose emerge.   
The exclusive use of male ICR mice in these experiments was based on one 
overlying factor, their relatively low cost.  The fact that these mice are outbred and are 
genetically different from each other may explain the variation in responses.  Ideally, 
experiments like these would have been conducted using inbred mice, such as BALB/c 
and C57BL/6, to eliminate one or more of the potential variables, such as genetic 
differences in P-450 activity.  Further experiments could be conducted using additional 
strains of mice and rats, among other laboratory animals, to ensure that the findings using 
the ICR mice were not aberrations. 
 Another avenue for further experiments entails the route of exposure to carbon 
tetrachloride.  The most common route of exposure to carbon tetrachloride in humans is 
via inhalation.  There have also been a number of oral exposures, either accidental or 
intentional, as well as dermal exposures.  As a matter of ensuring the delivery of the 
carbon tetrachloride, as well as minimizing the inhalation exposure of researchers and 
animal facility workers, the route of the dose used in the experiments was via 
intraperitoneal injection.  If research facilities were capable to consistently deliver a fixed 
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air concentration of carbon tetrachloride, and allow for the ability to maintain this level 
during administration of the PARP inhibitors as concomitant or delayed co-treatments, 
without exposing researchers in the process, the appropriate modification of previous 
studies for inhalation would be appropriate.  Dermal studies would best be served by 
selecting experimental animals which have less hair than ICR mice, because shaving 
mice may result in breakage of the skin, which may result in direct toxicant-blood 
contact.  Likewise, were ingestion experiments to be conducted in the future, they should 
be performed in experimental animals (e.g. rats) that are incapable of vomiting the 
toxicant, because regurgitation would result in diminished dosages.  In the alternative, if 
standardization of the concentrations of CCl4 in drinking water is deemed sufficient 
enough to control dosage, any laboratory animals could be given drinking water 
containing these fixed concentrations ad libitum. 
If one were interested in further understanding the details of the mechanism by 
which aminophylline attenuates the hepatotoxic effects of carbon tetrachloride and other 
free radical-mediated toxicants, in vitro studies may prove quite useful.  As was 
mentioned, the limited experiments using 6(5H)-phenanthridinone as a co-treatment with 
carbon tetrachloride in HepG2 cells strongly suggest that the mechanism involves the 
inhibition of PARP-1.  In conjunction with the inhibition of PARP-1, there may be an 
underlying inhibition of cytochrome P-450, specifically the CYP2E1 isoform of this 
enzyme, which is reported to generate trichloromethyl radicals via its reductive 
modification of carbon tetrachloride.  There may be some issues of concern that HepG2 
has limited cytochrome P-450 activity, specifically that of the CYP2E1 isoform.  
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However, there are cell lines of HepG2 cells that have been modified to have 
significantly elevated CYP2E1 activity.  Modified HepG2 cell lines have reportedly been 
produced, in which genes encoding for one or more P450 CYP isoforms have been 
artificially inserted into the genome.  Unfortunately, these cells could not be acquired in a 
timely fashion to allow for sufficient growth for the required experiments.  Future in vitro 
studies should incorporate the use of these cell lines in lieu of or in conjunction with 
HepG2 cells.  Also, the mechanism of action for the hepatoprotective effects of 
aminophylline should be further investigated in order to confirm that PARP is inhibited 
by aminophylline. 
Not only is aminophylline an inhibitor of PARP, it is also a nonselective 
phosphodiesterase inhibitor, which is believed to protect spinal neuron cells against 
damage caused by glutamate and reactive oxygen species (Nakamizo et al, 2003).  
Furthermore, the results of the TBARS assays suggest that aminophylline reduced the 
extent of CCl4-induced lipid peroxidation.  Therefore, PARP activity assays should be 
conducted to confirm that the hepatoprotective effects provided by aminophylline are 
directly related to its inhibition of PARP, instead of via some other mechanism.  However 
informative these possible cell culture experiments may be, they are no substitute for in 
vivo testing, because complex organisms are more than just a sum of their multitude of 
parts.  One critical example of this is that collections of cells from the same organ are not 
subject to the impacts of hormones, chemokines and other biological compounds arising 
from other organs or organ systems.  Also of importance is that there is no lag period 
between the time of dosage and exposure to the target cells in the case of in vitro studies, 
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whereas for in vivo experiments, toxicants have to be carried to their respective target 
organ by blood circulation or some other biological process. 
 Although carbon tetrachloride is considered a model toxicant, it should not be 
taken as gospel that aminophylline is equally protective against all free radical-mediated 
hepatotoxicants.  Ideally, each of the toxicants would be administered with and without 
aminophylline to multiple varieties of multiple species of animals.  Halogenated 
hydrocarbons of specific concern would most likely include dichloromethane, methyl 
bromide, formaldehyde, chloroform and others which are still in widespread use.  The use 
of methyl bromide as a fumigant was supposed to be phased out years ago, however in 
the absence of acceptable alternatives, this was significantly delayed.  The EPA has 
begun its phase-out in January of 2005, still allowing for quarantine and critical use, for 
which no other fumigant is effective (EPA, 2005).  As such, there is still the potential for 
fumigators to be exposed to methyl bromide, at least in the near future.  Formaldehyde is 
commonly used in resins, which are necessary for the construction and furnishing of 
buildings and mobile homes.  Many of the remainder of these compounds are used as 
solvents, degreasers and other products, which allow for possible overexposures, and 
aminophylline may prove to protect against their adverse effects. 
 Not all compounds have the same mechanism of action, so it must not be assumed 
that aminophylline would be capable of protecting against every hepatotoxicant.  
Preliminary unpublished experiments conducted in Dr. Harbisons laboratory suggest that 
aminophylline is not protective against bromobenzene-induced hepatotoxicity, the 
mechanism of which involves conjugation with glutathione.  This lack of protection may 
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not be indicative for all compounds, which involve glutathione conjugation, but that 
would require further experimentation.  Other possible mechanisms of toxicity include 
bile acid induced hepatocytes apoptosis, inflammatory liver injury, glutathione 
depletion, protein adduct formation/ peroxynitrite release, and induced mitochondrial 
dysfunction (Jaeschke et al, 2002).  As such, there are numerous opportunities for further 
studies, with the potential to significantly benefit mankind. 
 
Conclusion 
 Carbon tetrachloride is a model hepatotoxicant that has a free radical-mediated, 
non-glutathione dependant mechanism of action.  When added to the culture media for 
HepG2 human hepatocytes or administered by intraperitoneal injection to male ICR mice, 
carbon tetrachloride produced a series of hepatotoxic effects.  These effects included 
elevated relative LDH levels and PARP activity in the case of the HepG2 cells, as well as 
abnormally high serum ALT levels, increased lipid peroxidation and histopathology 
findings indicative of necrosis and apoptosis in the ICR mice.  The co-administration of 
PARP inhibitors, among them 6(5H)-phenanthridinone in the cell culture studies and 
aminophylline and nicotinamide in the animal studies, was capable of significantly 
protecting against these hepatotoxic effects associated with carbon tetrachloride.  These 
results strongly suggest that PARP inhibitors may effectively protect against the free 
radical-mediated non-glutathione dependent hepatotoxic effects of carbon tetrachloride 
and other compounds with similar mechanisms of action in humans. 
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